I8B-MC-ITSB (b) Protocol  
 
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-
Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type [ADDRESS_451399] 03740919 
  Approval Date: 30- Apr-2020  
I8B-MC-ITSB (b) Clinical Protocol Page 1
LY900014Protocol I8B-MC-ITSB (b)
A Prospective, Randomized, Double -Blind Comparison of 
LY900014 to Humalog with an Open -Label Postprandial 
LY900014 Treatment Group in Children and Adolescents 
with Ty pe 1 Diabetes
PRONTO -Peds
2018 -002371 -18 (EUDRA CTA )
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_105304]900014 ,unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries .  
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY900014
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_229490] 26 October 2018 .
Protocol amendment (a) electronically signed and approved by [CONTACT_362276]: 30-Apr-2020 GMT
I8B-MC-ITSB (b) Clinical Protocol Page 2
LY900014Table of Contents
Section Page
Protocol  I8B-MC-ITSB (b) A Prospective, Randomized, Double -Blind 
Com parison of LY900014 to Humalog with an Open -Label  
Postprandi al LY900014 Treatm ent Group in Children and 
Adolescents wi th Type [ADDRESS_451400] ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 15
3.1. Study  Rati onale ............................................................................................................ 15
3.2. Background .................................................................................................................. 15
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_451401] ions.................................................................................................... 28
6.4. Screen Failures ............................................................................................................. 28
7. Treatment s........................................................................................................................ 29
7.1. Treatments Administered ............................................................................................. 29
7.1.1. Packaging and Labeling ....................................................................................... 29
7.1.2. Medical Devices ................................................................................................... 30
7.2. Method of Treatm ent Assignment ................................................................................ 30
7.2.1. Selection and Timing o f Doses ............................................................................. 30
[IP_ADDRESS]. Target Gl ucose Val ues f or Ti tration of  Insulin Therapy .................................. 30
[IP_ADDRESS]. Timing of Doses ............................................................................................. 31
[IP_ADDRESS].1. Basal Insulin Adjust ment.......................................................................... 32
[IP_ADDRESS].2. Prandial Insulin Adjust ment...................................................................... 32
I8B-MC-ITSB (b) Clinical Protocol Page 3
LY9000147.3. Blinding ....................................................................................................................... 33
7.4. Dosage Modification .................................................................................................... 33
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_451402] to Follow -Up........................................................................................................ 38
9. Study  Assessments and Procedures ................................................................................... 39
9.1. Efficacy and Safet y Assessments .................................................................................. 39
9.1.1. Primary Efficacy  Assessments ............................................................................. 39
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 39
9.1.3. Safety Assessments .............................................................................................. 39
9.1.4. Appropriateness of Assessments .......................................................................... 40
9.1.5. Study  Procedures .................................................................................................40
[IP_ADDRESS]. Self-Moni tored Bl ood Gl ucose ....................................................................... 40
[IP_ADDRESS]. Use of Personal CGM or FGM ....................................................................... 41
9.2. Adverse Events ............................................................................................................ 41
9.2.1. Serious Adverse Events ........................................................................................ 42
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 43
9.2.2. Com plaint Handling ............................................................................................. 43
9.3. Treatment of Overdose .................................................................................................44
9.4. Safety........................................................................................................................... 45
9.4.1. Hypoglycemia ...................................................................................................... 45
9.4.2. Severe Hypoglycemia .......................................................................................... 46
9.4.3. Vital Signs, Hei ght, and Weight ........................................................................... 46
9.4.4. Laboratory  Tests .................................................................................................. 46
9.4.5. Immunogenicit y Assessments .............................................................................. 46
9.4.6. Safety Moni toring ................................................................................................ 47
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. 47
9.5. Pharmacokinet ics......................................................................................................... 48
9.6. Pharmacodynamics ...................................................................................................... 48
9.7. Pharmac ogeno mics ...................................................................................................... 48
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451403] ical Considerat ions........................................................................ 50
10.3.2. Treatment Group Comparabilit y........................................................................... 51
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 51
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 52
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 52
10.3.3. Efficacy Analyses ................................................................................................ 52
[IP_ADDRESS]. Primary Analyses ........................................................................................... 52
[IP_ADDRESS].1. Sensit ivity Analyses for Missing Data ....................................................... 53
[IP_ADDRESS].2. Addit ional Analyses fo r the Primary  Endpoint .......................................... 53
[IP_ADDRESS]. Secondary  Analyses ........................................................................................ 53
[IP_ADDRESS]. Terti ary/Exploratory  Analyses ........................................................................ 54
10.3.4. Safety Analyses .................................................................................................... 54
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 55
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 55
10.3.7. Other Analyses ..................................................................................................... 56
[IP_ADDRESS]. Subgroup Analyses ......................................................................................... 56
10.3.8. Interim Analyses .................................................................................................. 56
11. References ........................................................................................................................ 57
12. Appendices ....................................................................................................................... 59
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451404] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 60
Appendix 2. Clinical Laboratory  Tests ............................................................................... 64
Appendix 3. Study  Governance Considerat ions.................................................................. 65
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 69
Appendix 5. Sampling Summary ....................................................................................... 70
Appendix 6. Classificat ion of Contraceptive Methods ........................................................ 71
Appendix 7. Protocol  Amendment Hi story
......................................................................... 72
I8B-MC-ITSB (b) Clinical Protocol Page 6
LY9000141. Synopsis
Title of Stud y: 
A Prospective, Rando mized, Double -Blind Co mparison of LY900014 to Humalog with an 
Open -Label  Postprandi al LY900014 Treatment Group in Children and Ado lescents wi th Type 1 
Diabetes : PRONTO -
Peds
Rationale: 
The aim of this study  is to dem onstrate that an ultra -rapid formulation of insulin lispro, 
LY900014, i s noninferior to Humalog on glycemic control as measured by  [CONTACT_362277] 26 in hemoglo bin A1c ( HbA1c) in pediatric pat ients with type 1 diabetes (T1D), when 
administered in a double -blind manner as prandial insulin (0 to 2 minutes prior to the meal) in 
combinat ion with basal insulin.  
Objectives/Endpoints:
Objectives Endpoints
Primary Objective
1.To test the hypothesis that LY900014 is 
noninferio r to Humalog on glycemic control 
(NIM=0.4% for HbA1c) in patients 1 to <18 
years of age with T1D when administered as 
prandial insulin (0 to 2 minutes prior to the 
meal) in combination with basal insulin as
part of a multiple daily injection regimen for 
[ADDRESS_451405] the hypothesis that LY900014 
administered as postprandial insulin up to 
20minutes after the start of a meal 
(LY900014+20) is noninferior to Humalog , 
administered as prandial insulin (0 to 2 
minutes prior to the meal) , on gly cemic 
control (NIM=0.4% for HbA1c)2.Change f rom baseline to Week [ADDRESS_451406] the hypothesis that L Y900014 is 
superior to Humalog in improving glycemic 
control (HbA1c) when administered as 
prandial insulin (0 to 2 minutes prior to the 
meal)3.Difference between LY900014 and Humalog in 
change from baseline to Week 26 in HbA1c
Other Secondary Objectives
4.To compare LY900014, LY900014+20, and 
Humalog with respect to the incidence and 
rate of documented post-dose hypoglycemia4.Rate (events/patient/year) and incidence (percent age
of patients with events) of documented post-dose
hypoglycemic events within 1 and 2 hours after the 
prandial dose from Week s 0through 26
5.To compare LY900014, LY900014+20, and 
Humalog with respect to the incidence and 
rate of documented hypoglycemia5.Rate (events/patient/year) and incidence (percent age
of patients with even ts) of documented 
hypoglycemic events from Week s0 through 26
I8B-MC-ITSB (b) Clinical Protocol Page 7
LY9000146.To compare LY900014, LY900014+20, and 
Humalog on the rate of severe hypoglycemic 
events6.Rate (events/patient/100 years) of severe 
hypoglycemic events from Weeks 0 through 26
7.To compare LY900014, LY900014+20, and 
Humalog with respect to total, basal, and 
prandial insulin dose7.Change f rom baseline in total, basal, and prandial 
insulin doses and prandial/total insulin dose ratios at 
Week 26
8.To compare LY900014, LY900014+20, and 
Humalog with respect to the proportion of 
patients achieving HbA1c targets8.The proportion of patients with HbA1c<7% and 
<7.5% at Week 26
9.To compare LY900014, LY900014+20, and 
Humalog with respect to 7 -point SMBG9.Change f rom baseline to Week 26 in 7-point SMBG 
values
Abbreviations :  HbA1c = hemoglobin A1c ; NIM = noninferiority margin ; SMBG = self -monito red blood glucose; 
T1D = type 1 diabetes.
Summary of Study Design:   
Study  I8B-MC-ITSB (ITSB ) is a Phase 3, prospective, rando mized, outpatient, mult inatio nal, 
multicenter, parallel, act ive-controlled study  conducted in children and adolescent patients with 
T1D currently  using a multiple-daily -injecti on(MDI )regimen.  
Treatment Arms and Duration:   
The study  includes a 1- week screening with a 4-week lead-in period ,followed by a 26 -week 
treatm ent peri od and a 2-week safet y follow -up peri od.  In 2 of the treatment groups, LY900014 
and Humal ogwill be administered immediately  (0 to 2 minutes )prior to each meal in a 
doubl e-blind manner.  A thi rd open -label treatment group consists of LY900014 administered up 
to 20 minutes after the start of a meal (LY900014+20).  
Number of Patients:
Approximately  [ADDRESS_451407] imated total of 240completers per blinded treatm ent 
group and 120 completers for the open -label treatment group .  
Statistical Analysis:
The primary  analysis is for the treatment period through Week 26.
Efficacy analyses will be conducted on all rando mized patients according to the treatment the 
patients are assigned.  The analyses for the primary  and gated obj ectives will be performed for 
the efficacy  estimand, including data collected prior to permanent discontinuat ion of 
investigat ional pro duct (IP)and for the intention-to-treat (ITT)estimand ,including all data 
collected regardless of IP use.  The primary endpo int will also be analyzed using the 
Per-Protocol (PP) and Completer populat ions.
Safety analyses will be conducted on the Safet y popul ation.  Analyses of adverse events (AEs)
will include [ADDRESS_451408] set of analyses will include 
data collected prior to permanent discont inuation of IP.  The second set of analyses will include 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451409] non -missing measurement at or before the rando mizat ion 
visit (Visi t 4),unless otherwise specified.  
For the [LOCATION_002] ( US)Food and Drug Administration (FDA )submissio n (using the ITT 
estimand), the missing endpo ints will be imputed by [CONTACT_362278]. The reference 
for each treatm ent group is from the retrieved dropout patients who discont inue IP buthave the 
measurement at the primary  endpoint in the same treatment group . If there are only a limited 
number of patients in the reference group that leads
to a failure in performing the proposed 
multiple imputation analysis such that the m odel cannot converge , or the number of records in 
the reference group is less than the number of records with missing data, the missing endpo ints 
will be imputed by  [CONTACT_42036]-level observed baseline value plus a no ise,assuming a washout of 
any potenti al treatm ent effect (or “return to baseline”). The no ise follows a normal  distribut ion,
with the variabilit y estimated from  the “washout HbA1c data”. The “washout HbA1c da ta” will 
be derived by [CONTACT_362279] [ADDRESS_451410] between LY900014 and Hum alogfrom an analys is of 
covari ance (ANCOVA ).  The m odel for the change fro m baseline to the Week 26 HbA1c 
endpo int will include treatment and strata (pooled country , type of basal insulin, and age group ) 
as fixed effects and baseline HbA1c as a covari ate. The final est imates will be the combined 
estimates fro m at least [ADDRESS_451411] between LY900014 and Hum alogat Week 26 (Visit 15) f rom the mixe d-effect 
model repea ted-measure (MMRM )analysis of change fro m baseline in HbA1c ,including data 
collected from all rando mized patients prior to permanent discont inuat ion of IP through Week 26 
(efficacy  estimand).  
For both primary  analysis approaches, LY900014 will be declared noninferior to Humalog if the 
upper limit of the 2
-sided 95% confidence interval (CI)for the least-squares (LS)mean 
difference in the change from baseline in HbA1c for LY900014 minus Humal ogis below +0.4%.  
In addit ion, the 95% CI for the treatment difference will be co mpared to an alternat iveNIM of 
+0.3%.  Both estimands will be tested at the full significance level of 0.05 .  
A restricted maximum likelihood -based MMRM analysis will be use d to analyze cont inuous 
longitudinal variables.  All the lo ngitudinal observations at each scheduled postbaseline visit will 
be included in the analysis.  The model for the analysis o f the primary  efficacy  endpoint of 
change from baseline in HbA1c will inc lude the fixed class effects of treatment, strata (pooled 
country , type of basal insulin, and age group), visit , and treatment -by-visit interaction, as well as 
the continuous, fixed covariate of baseline value.  For analyses of variables other than HbA1c, 
I8B-MC-ITSB (b) Clinical Protocol Page 9
LY900014the HbA1c stratum ( ≤8.0%, >8. 0%) will be included in the model.  An unstructured covariance 
structure will be used to model the within-patient errors.  Si gnificance tests will be based on LS 
means and Ty pe III tests.  
An ANCOVA will also be used to analyz e cont inuous variables.  The model for the change fro m 
baseline to the Week 26 HbA1c endpo int will include treatment and strata (pooled country, type 
of basal  insulin, and age group) as fixed effects and baseline as a covariate.  Unless otherwise 
stated, m issing endpo ints will be imputed using the last -observat ion
-carried-forward (LOCF) 
approach, using only postbaseline data.  For analyses of variables other than HbA1c, the HbA1c 
stratum  (≤8.0%, >8. 0%) will be included in the mo del.
Hypoglycemia rates will be summarized for periods of 30 day s, 1year, and 100 years (severe 
hypoglycemia only ).  The rate of severe hypoglycemia per 100 y ears will be com pared between 
treatm ent groups using the empi[INVESTIGATOR_362263] (details will be described in statistical analysis 
plan[SAP]).  For each of the other categories of hypoglycemia, the number of hypoglycemia 
events during a specific period after randomizat ion (for example, Weeks 0 to 12 of treatment 
period) will  be analyzed by  [CONTACT_2329] a negat ive binomial regressio n model. The m odel will include 
treatm ent and age group ascovariate s.  An offset defined as the log transformat ion of treatment 
exposure in the specific period (day s)/365.25 days (or 30 days) will be included in the model to 
estimate the rate of hypoglycemia per year (or per 30 day s).  The proporti on of  patients wi th at 
least 1 hy poglycemic event in each category  during a specific period after randomizat ion will be 
analyzed usi ng a l ogisti c regressio n model including treatm entand age group as covariates .  
Contin uous safety  variables, as well as the change fro m baseline for these variables, will be 
analyzed by [CONTACT_362280].  For categorical variables, Fisher’s exact test or 
Pearson’s chi -square test will be used to compare treatment groups ,unless otherwi se specified.  
I8B-MC-ITSB (b) Clinical Protocol Page 10
LY9000142. Schedule of A ctivities
I8B-MC-ITSB (b) Clinical Protocol Page 11
LY900014Table ITSB .1. Schedule of A ctivities
Screen a Lead -In Treatment Perio dSafety 
Follow -UpEDb
eCRF Visit Number 1 2 3c 4 5c 6c 7 8c 9c 10 11c12 13c14c 15 801 d ED
Weeks from Randomization −5 −4 -2 0 2 4 6 8 10 12 15 18 21 24 26 28
Visit Window (±days) 3 3 3 7 7 7 7 7 7 7 7 7 7 7 7
Informed Consent /Assent (if 
applicable)X
IWRS X X X X X X X X X X X X X X X X X
Patient eligibility review X X
Randomization X
Clinical Assessments
Demographic data e X
Medical history , preexisting 
conditio nsX
Previous diabetes therapy X
Record Personal CGM/FGM use 
(yes/no)X
Height f X X X X X
Weight X X X X X X X X
Vital signs (sitting SBP, DBP ,and 
HR) gX X X X X XXX
Concomitant medications X X X X X X X X X X X X X X X X X
Adverse events and product 
complaintsX X X X X X X X X X X X XXX X
Focused physical exam (including 
skin evaluation)h X X X X X XXX
Basal insulin dose assessment i X X X X X X X X X X X X X X X
Basal insulin dose titrationjX X X X X X X X X
I8B-MC-ITSB (b) Clinical Protocol Page 12
LY900014Screen a Lead -In Treatment Perio dSafety 
Follow -UpEDb
eCRF Visit Number 1 2 3c 4 5c 6c 7 8c 9c 10 11c12 13c14c 15 801 d ED
Weeks from Randomization −5 −4 -2 0 2 4 6 8 10 12 15 18 21 24 26 28
Visit Window (±days) 3 3 3 7 7 7 7 7 7 7 7 7 7 7 7
Prandial insulin dose assessment X X X X X X X X X X X X X X X
Prandi al insulin dose titration i X X X X X X X
Ancillary Supplies/Diaries/IP
Dispense blood glucose meter and 
ancillary  supplies and complete 
training k,lX X X X X
Diabet es education and nutrition 
counseling lX
Dispen se study diaries and 
complete training lX X X X X
Collec tstudy diaries X X X X X X
Dispense IP X X X X X
Train o n collecting 4 -and 7-point 
SMBG profiles mX
Remind patient of 7 -point SMBG 
requirementsX X X
Review and discuss SMBG
(and/o r CGM/FGM) and 
hypoglycemia data from patient 
study diaryX X X X X
Discuss SMBG (and/or 
CGM/FGM) and hypoglycemia 
data with patientX X X X X X X X
Review/di scuss only  severe hy po 
data after completion of study 
treatmentX
I8B-MC-ITSB (b) Clinical Protocol Page 13
LY900014Screen a Lead -In Treatment Perio dSafety 
Follow -UpEDb
eCRF Visit Number 1 2 3c 4 5c 6c 7 8c 9c 10 11c12 13c14c 15 801 d ED
Weeks from Randomization −5 −4 -2 0 2 4 6 8 10 12 15 18 21 24 26 28
Visit Window (±days) [ADDRESS_451412], serum/urine 
(applicable females only) nX X
Urinaly sis (screening) X
HbA1c X X X X X X
Clinical chemistry X X X
Hematology X X X
Antilispro antibodies X X X X X X
I8B-MC-ITSB (b) Clinical Protocol Page 14
LY900014Abbreviations: DBP = diastolic blood pressure; eCRF = electronic case report form; ED= early discontinuation; HbA1c = hemoglobin A1c; HR= heart rate; IP
= investigational product; IWRS = interactive web-response sy stem; SBP = systolic blood pressure; SMBG = self -monito red blood glucose ; WHO = World 
Health Organization.
aPatients who rescreen will start at Visit 1 ..
bRandomized p atients who decide to discontinue will be asked to return for the ED visit. If a p atient discontinue sduring an office visit that visit may be 
treated as the ED visit.  If a patient discontinues via telephone, they will be asked to return for the ED visit.
cTelepho ne visits are indicated by [CONTACT_317757]. Telephone visits can become office visits. Site documentation will serve as the source for telephone visits .
dV801 will be a telephone visit; this visit can become an office visit.  
eMedical history to include investigator review of immunization status with patient and caregiver.
fIn order to obtain accurate measurements , length should be measured using an infantometer and height should be measured using a stadiometer (WHO Child 
Growth Standards).   
gBlood pressure measurements should be determined correctly, using the appropriate -size dcuff for the child’s age and with the child seated and relaxed.
hA qualified medical professional must perform a medical assessment at each site visit.  During each office visit, the skin surrounding the injection site sshould 
be assessed .  
iBasal insulin dose assessment should be made during the lead -in period and as needed during the study .  
jBasal insulin should be adjusted during the lead-in period so as to achieve or maintain BG targets with a focus on the prebreakfast BG .  Prandial insulin 
should be titrated with an emphasis during the first 12 weeks after randomization in order to reach optimal dosing and achieve BG targets .  Adjustment of 
basal and prandial insulin doses may continue throughout the 26-week treatment period in order to achieve or maintain glycemic targets based on changes in 
lifesty le, individual circumstances or for safety reasons.  
kGlucose monitoring supplies will be dispensed at each office visit, as needed.  
lInitial training at Visit 2may include diabetes education and nutrition counseling. 
Appropriate site personnel will administer training and education using 
locally approved diabetes education/training materials or other materials provided by [CONTACT_456] .Patients may be provided abbreviated t raining and 
education at visits following Visit 2,as appropriate .  
mPatients who wear personal CGM/FGM approved for dosing decisions may be trained to use their sensor data for [ADDRESS_451413] be performed in female patients of childbearing potential (see inclusion criterion [9]) at Visit [ADDRESS_451414] 
within 24 hours prior to IP exposure at randomization (Visit 4) and at other times at the investigator’s discretion. When required per local regulations and/or 
institutional guidelines, local pregnancy testing will occur at mandatory times during the study treatment period.
I8B-MC-ITSB (b) Clinical Protocol Page 15
LY9000143. Introduction
3.1. Study Rationale
Young children wit h type 1 di abetes (T1D )are susceptible to glucose variabilit y due to increased 
insulin sensit ivity and unpredictable eat ing and physical act ivity.  Often, their cognit ive 
immaturit y and inabilit y to verbalize symptom s present a challenge forrecogni zing and treating 
hypoglycemia .  It i s well known that fear of hy poglycemia, parti cularly  among parents of 
children with diabetes, impacts T1D management and qualit y of life.Children wit h T1D 
experience different insulin requirements due to increasing weight, height, and caloric needs , 
which poses challenges wit h glucose control  and insulin therapy .  The current rapi d-acting 
insulin analogs are not as fast and asshort -acting as needed to meet these challenges. A prandial 
insulin with faster onset and/or faster offset characterist ics might reduce glycemic excursio ns and 
decrease the incidence of delayed postprandial hypoglycemia co mpared to currently available 
rapid-acting insulin analogs.  LY900014 is an ultra -rapid -acting insulin lispro formulat ion with 
increased early absorption compared to Huma log®; Eli Lilly and Co mpan y.  LY900014 aims to 
mimic the physio logical prandial insulin secret ion pattern, whi ch may  more effect ively control  
postprandial glucose (PPG) excursio ns.  
The aim of this study  is to dem onstrate that an ultra -rapid formulation of insulin lispro, 
LY900014, i s noninferior to Humalog on glycemic control as measured by  [CONTACT_362277] 26 in hemoglo bin A1c (HbA1c) in pediatric patients with T1D, when administered in a 
doubl e
-blind manner as prandial insulin in combination with basal insulin.  
3.2. Background
Regional evidence suggests that the incidence of T1D in y outh is increasing in the United 
States (US;Lipman et al. 2013) and Europe (EURODIAB ACE Study  Group 2000).  Estimate s 
of T1D preval ence in the pediatricpopulati on in the US com e from the Centers for Disease 
Control  and Prevent ion–sponsored SEARCH for Diabetes in Youth Study  Group (SEARCH ).
The SEARCH study  estimated that in 2011 ,the total number of y outh in the US <2 0 years of age 
with T1D was 166,984 (Pettit tet al. 2014).
As wi th adul ts, intensive diabetes management through maintenance of tight glycemic control  
helps to delay  onset and sl ow the progressi on of  complicat ions of the disease in 
youth(DCCT 1993).  Ti ght glycemic control  is achieved via intensive insulin therapy , which 
requi res dietary  discipline, frequent blood glucose (BG) monitoring, and m ultiple inject ions of 
insulin (both rapid
-and l ong-acting insulin) to mimic the natural pattern of insulin releas e, the 
combinat ion of which represents a major burden on the patient, especially youth.  Intensive 
insulin treatment in T1D should be init iated early in disease progression and the improved 
glycemic control  may have a l asting impact on reducing the onset o f diabetic com plicat ions.  
There have been many  advances in the treatm ent of T1D in the last 20 y ears; however, reaching 
and maintaining glycemic goals remain challenging even under intensive insulin therapy 
regimens.  Only ,approximately ,30% of  insulin -requi ring diabetes patients are able to reach the 
goal HbA1c target of <7% (Casagrande et al. 2013).  Currently  available rapid -acting insulin 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451415] ion, 16.3% of patients indicated that they  inject 15 minutes 
prior to m eals, 33% inject 1 to14minutes prior to meals, 38.6% inject at the time of the meal, 
and 12.1% inject after the start of a meal.  Because pati ents often inject later than recommended ,
there is a greater mismatch between insulin act ion and postprandial BG elevations.  With 
postm eal dosing, the mismatch between the rise in BG and the onset of insulin act ion is even 
more pronounce d.  For the development of a
nultra-rapid insulin , it will be important to 
understand the relat ionship between the time- actionprofile of the insulin, insulin inject ion 
timing, and meal t iming in order to maximize improvements in postprandial glycemic cont rol 
and minimize hypoglycemia risk.  A ninsulin with higher early concentration and peak exposure 
along wi th a shorter duration shoul d improve early postprandial control and limit postmeal 
hyperglycemia while reducing late postprandial hypoglycemia due to lower insulin exposure.  
A new pharmaceutical inno vation that m ay all ow m ore effect ive control of PPG levels i s 
LY900014, a new formulat ion of insulin lispro developed as an ultra- rapid-acting insulin with a 
faster onset of action and shorter duration of act ion com pared to currently  available rapi d-acting 
insulin analogs.  The changes in pharmacokinet ic and pharma codynamic ( PK and PD)
characterist ics are achieved by [CONTACT_362281] (FDA) as excipi[INVESTIGATOR_840].   
Treprostinil ,as an excipi[INVESTIGATOR_841] ,enhances the absorpti on of insulin lispro by  [CONTACT_362282] a systemic effect.  
Treprostinil has 
been approved in the USsince 2002 (Rem odulin package insert, 201 8) and in Europe since 2005 
(PMR [WWW]).  Sod
ium citrate, an excipi[INVESTIGATOR_362264], is also included in 
the form ulation to further enhance the absorption of insulin lispro.  Furthermore, the excipi[INVESTIGATOR_362265]900014 is wit hin the limit s identified for approved drug produ cts in the FDA 
Inact ive Ingredients in Approved Drugs database.
Please refer to the Humalog local product labeling (for example , Hum alog package insert, 201 7; 
Hum alog Summary  of Product Characteri stics
, 201 8) for more inform ation regarding Humal og.
The Investi gator’s Brochure (IB) describes the clinical and nonclinical development of 
LY900014 .  
3.3. Benefit/Risk Assessment
The faster action profiles seen wit h rapi d-acting insulins o ffer the potential to more safely and 
effect ively simulate norm al insulin pro files in patients with T1D with earlier and higher peaks 
and shorter duration of action. Yet,it is apparent that the absorption rate sof currently available 
rapid-acting insulin analogs are still not fast enough to eliminate postmeal hyperglycemia and 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451416] ,in which the risk of hypo glycemia (potenti ally severe in very  young children) 
outwei ghs the risk of postm eal hyperglycemia in this populat ion. Study  ITSB will include an 
open -label treatment group to study  dosing when given up to [ADDRESS_451417] of pediatri c clinical trials .  Frequent interaction with site staff will 
occur and allow for careful mo nitoring of BGvalues and hypoglycemic events .  In order to 
minimize risk and disco mfort forpatients, the number of procedures (including blood draws) and
office visit shas been reduced to decrease time l ost fro m work andschool . 
Across all doses in the Eli Lilly and Co mpany (Lilly) clinical studies that have evaluated 
treprostinil as a local vasodilator with or without insulin lispro, there was no clinically  significant 
increase in adverse events ( AEs) associated with systemic absorption of treprostinil, as described 
in the Remodulin package insert (2018; that is, headache, diarrhea, nausea, jaw pain, 
vasodilatati on, edem a, and hypotensio n).  
There are limited data on the use of treprostinil in pediatric patients.  Pediatric assessments have 
not been required for treprostinil because of its orphan drug desi gnati on; thus, the safet y and 
effect iveness of treprostinil in pediatric patients have not been established (Remodulin package 
insert, 2018 ; Tyvaso prescribing informat ion, 2014; Orenitram prescribing informat ion, 2016).  
Subcutaneous (SC) trepros tinil has been evaluated in children wit h pulmo nary artery  
hypertensio n (PAH )in an observat ional study  (n=8).  Six children had symptomatic and 
hemodynamic response sto the addi tion of  SC treprostinil, wit h manageable control of local 
inject ion
-site disco mfort (Levy  et al . 2011). A clinical study  I8B-MC-ITSA (Study  ITSA) is 
ongoing. The aim o f Study  ITSA is to evaluate PK, PD , safet y, and tol erabili ty of LY900014 in 
comparison wi th Hum alog following a single subcutaneous (SC) dose administration 
immediat ely prio r to a standardized liquid meal .  Study  ITSA isthe first study  to eval uate 
LY900014 in pediatri cpatients with T1D .  
Preschool children o ften need proportionally larger bolus insulin doses, often const ituting 60% to 
80% of the total daily insulin dose (TDD ; Sundberg et al. 2017).  Study  ITSB will allow a 
maximum TDD of 1.5 U/kg.  Assuming a TDD of 1.2 U/kg and body weigh t of 80kg, a total 
insulin bolus dose would be administered in [ADDRESS_451418] ion in adult Phase
I8B-MC-ITSB (b) Clinical Protocol Page 18
LY9000141b studi es, treprostinil has been undetectabl ein the sy stemic circulat ion.  In addi tion, there were 
no detectable treprostinil drug concentrations with continuous subcutaneous insulin infusio n 
(CSII )therapy  during the basal infusio n or after the bo lus dose samples from pat ients with T1D.
Thus, the expected treprostinil maximum drug concentration (Cmax)following LY900014 
administration would be below the assay quantitation limit of 0.010 ng/mL and would be 
approximately  200-fold lower than the average steady -state treprostinil levels in adult PAH 
patients treated with Remodulin .  The exposures of treprostinil in LY900014 are expected to be 
substant ially lower than those observed in the treatment of PAH.
Females of child -bearing potential can parti cipate in this study  if they test negative for pregnan cy 
at study  entry  and agree to m aintain sexual abstinence or use a highly effect ive method of 
contraception throughout the study . In a fertilit y and early embry onic devel opment study  in 
male and female rats, there were no adverse effects of treprostinil on sperm morpho logy, estrus 
cyclicity, mating, fertilit y, concept ion, implantation, and embryo nic survival.  Embry o-fetal 
developmen t studi es indicated that treprostinil was not teratogenic in rats or in rabbits.  In a 
prenatal  and postnatal  devel opment study  in rats, there was no evidence of maternal toxicit y or 
adverse effects on offspring growth, behavior, and reproductions.  
More informat ion about the known and expected benefits, risks, serious AEs (SAEs), and 
reasonably  anticipated AEs of LY900014 can be found in the IB.  More detailed information 
about the known and expected benefit s and risks of Humal ogmay be found in the count ry-
specific product labeling (for example, Patient Informat ion Leaflet, Package Insert, or Summary 
of Product Characterist ics).
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451419] the hypothesis that LY900014 is 
noninferio r to Humalog on glycemic control 
(NIM=0.4% for HbA1c) in patients 1 to <18 
years of age with T1D, when administered as 
prandial insulin (0 to 2 minutes prior to the meal ) 
in combination with basal insulin as part of a 
multiple daily injection regimen for [ADDRESS_451420] the hypothesis that LY900014 
administered as postprandial insulin up to 
20minutes after the start of a meal 
(LY900014+20) is noninferior to Humalog ,
administered as prandial insulin (0 to 2 minutes 
prior to the meal ), on glycemic control 
(NIM=0.4% for HbA1c)2.Change f rom baseline to Week [ADDRESS_451421] the hypothesis that LY900014 is superior 
to Humalog in improving glycemic control 
(HbA1c) when administered as prandial insulin
(0 to 2 minutes prior to the meal )3.Difference between LY900014 and Humalog in 
change from baseline to Week 26 in HbA1c
Other Secondary Objectives
4.To compare LY900014, LY900014+[ADDRESS_451422]-dose hypogly cemia4.Rate (events/patient/year) and incidence (percent age
of patients with events) of documented post-dose
hypoglycemic events within 1 and 2 hours after the 
prandial dos e from Week s0 through Week 26
5.To compare LY900014, LY900014+20, and 
Humalog with respect to the incidence and rate 
of documented hypoglycemia5.Rate (events/patient/year) and incidence (percent of 
patients with events) of documented hypogly cemic 
events from Week 0 through Week 26
6.To compare LY900014, LY900014+20, and 
Humalog on the rate of severe hypoglycemic 
events6.Rate (events/patient/100 years) of severe 
hypoglycemic events from Weeks 0 through 26
7.To compare LY900014, LY900014+20, and 
Humalog with respect to total, basal, and 
prandial insulin dose7.Change f rom baseline in total, basal, and prandial 
insulin doses and prandial/total insulin dose ratios at 
Week 26
8.To compare LY900014, LY900014+20, and 
Humalog with respect to the proportion of 
patients achieving HbA1c targets8.The proportion of patients with HbA1c <7% and 
<7.5% at Week 26
9.To compare LY900014, LY900014+20, and 
Humalog with respect to 7 -point SMBG9.Change f rom baseline to Week 26 in 7-point SMBG 
values 
Tertiary/Exploratory Objectives
I8B-MC-ITSB (b) Clinical Protocol Page 20
LY90001410.To compare LY900014, LY900014+20, and 
Humalog with respect to changes in body weight10.Change in weight (kg) from baseline to Week 26
11.To compare LY900014, LY900014+20, and 
Humalog with respect to glycemic variability11.Within -day and between -day glycemic variability 
measured by [CONTACT_362283] 7-point SMBG profiles
12.To compare the incidence of treatment -emergent 
anti-insulin lispro antibodie s for LY900014, 
LY900014+20, and Humalog12.Incidence of treatment -emergent anti -insulin lispro 
antibodies
Abbreviations:  HbA1c = hemoglobin A1c ; NIM = noninferiority margin ;SMBG = self -monito red blood glucose; 
T1D = type 1 diabetes .
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451423] ion (MDI )regimen.  In 2 of the treatment groups, 
LY900014 orHumalog will be administered immediately (0to 2 minutes ) prior to each m eal in a 
doubl e-blind manner. A thi rd open -label treatment group consists of LY900014 administered 
upto 20 minutes after the start of a mea l (LY900014+20).  It is not possible to blind this 
treatm ent group as it uses a different inject ion timing. The study  is designed to demonstrate 
noninferiorit y of LY900014 when compared wit h Hum alogin change fro m baseline to Week 26 
in HbA1c, when both a re administered at the start of the meal.  The study  includes a 1-week 
screening with a 4-week l ead-in period followed by  a 26 -week treatm ent peri od and a 2-week 
safet y follow-up peri od.  
The purpose of the lead -in period is to obtain blood glucose (BG) values along wi th basal  and 
prandial insulin doses to assess basal and meal time insulin dosing and to determine baseline 
hypoglycemia rates .  Basal insulin should be titrated by [CONTACT_362284] -
inperiod, in anticipation o f increas ed act ivity or individual patient needs, so as to achieve or 
maintain glucose targets (Table ITSB. 4) with an emphasis on the pre -breakfast BG.  
Invest igators will  have access to a patient’s glucose values ;so,they may assist pati ents and 
caregivers wit h appropriate basal adjust ments. The l ead-in will also allow pat ients and 
caregivers to beco me familiar wi th the pati ent study  diary and the docum entati on requi red 
throughout the study .  
Patients treated with insulin glargine U -100 once a day  (QD) or twi ce a 
day (BID ), insulin detemi r U-100 QDor BID orinsulin degludec U -100 QD will be eligible for 
inclusio n in the trial.  At Visit 2, pati ents will continue their allowed study  basal insulin regimen
at the same dosing frequency ( QDor BID). Patients should remain onthe same basal insulin 
throughout the study; switching brands should be avo ided when possible .  
During the l ead-in period, p atients will be switched to open -label marketed insulin lispro 
(Hum alog)using a unitfor unit conversio nor the dose may be determined based on the 
investigator’s clinical judgement .  
Prandial insulin doses will be assessed at Vi sits 2and 3 .
Adjustments to dose and dosing calculat ions may be necessary at randomizat ion(Visit 4) to
minimize the risk of hypoglycemia or hyp erglycemia.
Diabetes educat ion and nutrit ion counseling ,including hypoglycemia recognit ion and 
management should be provided .  
Accuracy of carbohydrate coun ting shoul d be assessed for 
those patients who dose mealt ime insulin based on carb content .  Appropriate site personnel will 
administer training and educat ion as needed using locally approved diabetes educat ion/training 
materi als and program s or other m aterials that m ay be provi ded by [CONTACT_456]. Patients may be 
provi ded additional focused training and educat ion at vi sitsfollowing Vi sit 2 based upon pati ent 
needs.
At Visit 4, pati ents will  be randomized to ei ther blinded LY900014 or Humalog to be given at 
mealt ime(0 to 2 minutes prior to the meal) or open -label LY900014 given up to 20 minutes after 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451424] 12 
weeks in order to reach optimal dosing and achieve glucose targets (TableITSB. 4).  Adjustment 
of basal  and prandial insulin doses may  cont inue throughout the treatment period in order to 
achieve or maintain glycemic targets based on changes in lifestyle, individual circu mstances or 
for safet y reasons .  
After complet ion of study  treatm ent (Visi t 15or early discontinuation [ ED]), it is recommended 
that pati ents return to their pre -study  prandial insulin; however, the cho ice o f insulin therapy 
shoul d bemade by [CONTACT_362285] .  
Study  governance considerations are described in detail in Appendix [ADDRESS_451425] scheduled procedure shown in the Schedule o f 
Activities(Secti on 2,Table ITSB .1)for the last patient .

I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451426] ion timing of LY900014 (up to 20 minutes after the start of a meal) and 
will evaluate the efficacy  and safet y of postprandi al dosing .  The recommended time of 
administration of current ly marketed rapi d-acting insulins is before meals, butpatients often 
inject later than recommended . The study  is desi gned to com pare a decrease in HbA1c as the 
primary  endpoint . The HbA1c is a measure of glycemic control accepted by  [CONTACT_362286] a validated measure of BG control  over time and is a
marker for development and progression of diabetes complicat ions.  A 4-week lead -in period
will provide thetime needed for patients taking insulin aspart or insulin glulisine , or biosimilar
insulin lispro at screening to swi tch to marketed insulin lispro ( Humalog )with anemphasis on 
basal insulin adjust ment and optimizat ion
.  While basal insulin may continue to be adjusted to 
achieve FBG targets during the 26-week treatm ent peri od, prandial insulin should be titrated with 
anemphasis on achieving optimal dosing during the first [ADDRESS_451427] the same insulin lispro concentration (100 U/mL) as that of co mmercially 
available Humalog.  The addit ion of treprostinil
to the insulin lispro formulat ion does not modify 
the physical, chemical, or biological integrit y of insulin lispro.  The dosage of basal and prandial 
insulins used in this study  shoul d be determined based on the individual needs of each pat ient.
I8B-MC-ITSB (b) Clinical Protocol Page 24
LY9000146.Study  Population
Prospective approval o f protocol  deviati ons forrecruitment and enrollment criteria, also known 
as protocol waivers or exemptions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study ,only if they meet all  the f ollowing cri teria at 
screening:
Type of Patient and Disease Characteristics
[1]Male or female pat ients with T1D for at least [ADDRESS_451428] (pedi atric or adul t), diabetes specialist , or a physician with 
expert ise in treating pedi atric pat ients with Type 1 di abetes .
Patient Characteristics
[2]Are at l east 1 to <18 y ears of age .
[3]Are ≥16lbs.(7.3 kg) .
[4]Have been treated with only one of the f ollowing rapid-acting insulin analog s
as part of a n
MDI regimen for at least the last 90 days: 
a.insul in lispro U -100, or 
b.insulin aspart 
c.insulin glulisine or
d.Fast acting insulin aspart ( must be approved for use in children in 
accordance with the l ocal product l abel)
[5]Have been treated with only 1of the f ollowing basal  insulins for at least the 
last 90 day s: 
a.insulin glargine U- 100 (QD or BID) , or
b.insulin detemir U- 100 (QD or BID) , or
c.insulin degludec U -100 ( QD)
[6]Use a t otal daily dose of insulin 0.3 to ≤1.9 U/kg.
a.TDD can be theaverage of previous 3 to 7 days
[7]Have a
HbA1c value ≤9.9% accordi ng to the central  laboratory .  
[8]Male patients: 
a.no male contraception required ,except in co mpliance wit h specific local 
government regulat ions
[9]Female pat ientsof childbearing potential:
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451429] pubertal females o f childbearing potential are defined as children and 
adolescents ≥12 y ears of age or <[ADDRESS_451430] agree to use 1 highly  effective form  of 
contraception for the ent irety of the study  (Appendix 6 )
c.not pregnant or intending to become pregnant
i. post pubertal females of childbearing potential must test negative for 
pregnancy prior to init iation of treatm ent as indicated by  a negat ive 
serum pregnancy  test at the screening visit followed by  a negat ive 
urine pregnancy test within [ADDRESS_451431] ( IP)at Visit 4
d.
not breastfeeding
Other Study Requirements forPatient or Caregiver
[10] Hasrefrigerat ion in the ho me or hasaccess to refrigeration for storage of 
insulin .  
[11] Arecapable and willing (as determined by  [CONTACT_17062] ) to do the 
following:
a.inject insulin wit h the use of an insulin pen injection device according to 
written instructions
b.perform  fingerst ick SMBG as requi red by [CONTACT_362287] m eter provi ded
EXCEPTION: patients using personal continuous glucose 
monitoring ( CGM )or flash gl ucose m onitoring (FGM )device s
that are consistent wit
h local country  regulati ons and approved 
for use for insulin dosing decisi onsmay usethemfor 4 -point 
glucose testing during the study (see Secti on [IP_ADDRESS] ).
c.record all informat ion in study  diaryas requi red by [CONTACT_3181]
d. follow instructions for basal insulin adjust ment and individualized 
prandial insulin dosing using fixed -pattern adj ustment or carbohy drate 
counting ,as provi ded by [CONTACT_3170]
e.comply with the use of study  insulin and scheduled visits
Informed Consent
[12] The child/ado lescent and/or a parent or legal guardian are able to understand 
and willingly partici pate fully in the activit ies of the clinical trial and sign 
their age and developmentally  appropri ate assent and consent, asrequired
per local guidelines .
I8B-MC-ITSB (b) Clinical Protocol Page 26
LY9000146.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions
[13] Have current hy poglycemic unawareness in the investigator’s opi[INVESTIGATOR_362266] m ore than 1 epi [INVESTIGATOR_66677] (defined as requiring 
assistance due to neurologically disabling hypoglycemia, indicated by [CONTACT_362288] n and/or use of intravenous glucose or gl ucagon ) within 
6months pri or to screening (Visit 1).
[14] Have had more than 1 emergency room visit or hospi[INVESTIGATOR_362267]  (hyperglycemia or diabet ic ketoacidosis) within 6 mo nths 
prior to screening (Visit 1) .  
[15] Have any other clinically sign ificant disorder or uncontrolled concomitant 
disease that, in the invest igator's opi[INVESTIGATOR_3078] n, woul d precl ude part icipation in the 
trial or pose a safet y risk. 
[16] Renal: 
a.history  of renal  transplantati on,
b.currently receiving dialysis , 
or 
c.have a history  of renal impairment (exclusio n only if glo merular 
filtrat ion rate [estimated GFR] <60 mL/minute/1.73 m 2as defined by 
[CONTACT_19690] .
[17] Have obvious clinical signs or symptoms o f liver disease in the opi[INVESTIGATOR_3078] n of 
the invest igator (for example , acute or ch ronic hepati tis or ci rrhosis) or 
elevated liver enzyme measurements as indicated below at screening:
a.total bilirubin ≥2× the upper limit of normal (ULN) (with the except ion 
of Gilbert ’s disease) as defined by [CONTACT_2237] , or
b.alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase 
≥3×ULN as defined by [CONTACT_2237] ,or
c.aspartate aminotransferase (AST)/serum glutamic oxaloacetic 
transaminase ≥
3×ULN as defined by  [CONTACT_19690]
[18] Active or untreated malignancy or in remissio n from clinically significant 
malignancy (other than basal cell or squamous cell skin cancer) for less than 
5 years .  
[19] Known hypersensit ivity or allergy  to any  of the study  insulins or their 
excipi[INVESTIGATOR_840] .  
I8B-MC-ITSB (b) Clinical Protocol Page 27
LY900014[20] Blood transfusio n or severe blood los s within [ADDRESS_451432] known hemoglobinopathy, anemia, hemo lytic anemia, sickle cell 
anemia, or any  other trai ts of hemoglo bin abnormalit ies known to interfere 
with the HbA1c measurement .  
[21] Have history  of inpatient psychiatric treatmen t;emoti onal, behavi oral, or 
other untreated condit ions that , in the opi[INVESTIGATOR_3078] n of the invest igator, would 
interfere wi th proper parti cipat ion in routine diabetes control and 
management in the last 6 months.
[22] Have significant lipohypertrophy .  
[23] Retinopathy  and maculopathy:  have preproliferat ive and proliferat ive 
retinopathy , or m aculopathy requi ring treatm ent or not clinically  stable in 
the last [ADDRESS_451433] 6 months.
Note:  Patients with a history  of preproliferat ive retinopathy , proliferat ive retinopathy, or 
maculopathy that remains stable at least [ADDRESS_451434] igator’s judgment should continue to attend 
appropriate periodical eye examinations with an ophthalmo logist.  If an eye examinat ion 
has been performed no more than [ADDRESS_451435] to be 
repeated; however, the inves tigator will need to confirm via interview that there is no 
change in subject ive symptoms.
Prior/Concomitant Therapy
[24] Receiving chronic (last ing longer than 14 consecutive days) systemic 
glucocorti coid therapy (excluding topi[INVESTIGATOR_2855], intraocular, intranasal, an d 
inhaled preparations) or have received such therapy within the last 90 day s.
[25] Have been on a treatment regimen that includes regular human insulin , 
neutral  protamine Hagedorn (NPH ), Afrezza ® (insulin human )inhalation 
powder , any premixed insulins or use of diluted insulins within the last 90 
days.  
[26] Receiving any oral or injectable medicat ion intended for the treatment of 
diabetes m ellitus other than insulins within the last 90 days.
[27] Have been treated by  [CONTACT_362289] ≥[ADDRESS_451436] 90 da ys.
Prior/Concurrent Clinical Trial Experience
[28] A
re current ly enrolled in any other clinical study  involving an IPor any  
other ty pe of medical research judged by [CONTACT_362290] h this study .
I8B-MC-ITSB (b) Clinical Protocol Page 28
LY900014[29] Have par ticipated, wi thin the last 30 days, in a clinical study  involving an 
IP, except for Study  I8B-MC-ITSA (ITSA) .Patients may be considered for 
screening in this trial immediately upon ED or complet ion of Study  ITSA 
(Parts A and B). No additional wait ing period is necessary  between 
participat ion in ITSA and ITSB .
Other Exclusions
[30] The patient or caregiver a re invest igator site personnel direct ly affiliated 
with this study  or a m ember of their immediate families.  Immediate family 
is defined as a spouse, pa rent, child, or sibling, whether bio logical or l egally 
adopted .
[31] The patient or caregiver is animmediate family member of Lilly  empl oyees 
(including emplo yees, tem porary  contract workers, or designees responsible 
for the conduct of the study ). Immediate f amily is defined as a spouse, 
parent, child, or sibling, whether bio logical or legally  adopted .
6.2.1. Rationale for Exclusion of Certain Study Candidates
The use of LY900014 in pediatri c patients is ant icipated ;thus,this study  will specifically 
examine the safet yand efficacy  in a pediatri cpopulat ion.  Criteri on[1] and Criterion[ 2] define 
the popul ation needed for the purposes of this study .  Therefore, pati ents not m eeting the
se
criteria are excluded.
6.3. Lifestyle Restrictions
Not applicable.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) or were 
requi red to unexpected ly discont inue from the study during screening or lead -in period (e.g., due 
to enrollment pa use related to the COVID -19 public healt h emergency )are allowed 
1rescreening. 
Allpatient s that rescreen will restart at Visi t 1 and com plete all  screening procedures . 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451437] open- label treatment group, 
LY900014 will be administered up to 20 minutes after t he start of a mea l (LY900014+20) f or 26 
weeks .
Table ITSB .3shows the treatment regimens.
Table ITSB .3. Treatment Regimens
Regimen Dose
StrengthDose
AdministrationRoute of
AdministrationTiming of 
Administration
LY900014 100 U/mL Individualized 
dosingSubcutaneous 0 to 2 minutes before start of the meal
Humalog 100 U/mL Individualized 
dosingSubcutaneous 0 to 2 minutes before start of the meal
LY900014[PHONE_7462] U/mL Individualized
dosingSubcutaneous Up to [ADDRESS_451438] igator or his/her designee is responsible for
explaining the correct use of the IP to the patient 
oincluding the importance of injection site rotation for both basal and prandial 
insulin 
explaining study  diary requi rements for recording insulin doses and inject ion 
times to the pati ent
verifying that all study  instructions are fo llowed properly
maintain ing accurate records of IP dispensing and collect ion
confirming that the patient returns all unused IP to the site 
7.1.1. Packaging and Labeling
Clinical trial materials will be labeled as IP as appropriate and according to the country’s 
regul atory  requi rements.  Study  insulins ( LY900014 and Hum alog) will be supplied by [CONTACT_362291], in accordance wit h current good manufacturing prac tices, and will be supplied 
with clinical  trial lot numbers.  Instructi on for Use for the prefilled pen devices will be provided.
The blinded prefilled pens will contain a concentration of 100 U/mL in 3 -mL cartri dges of ei ther 
LY900014 or Humalog .  The ope n-label prefilled pens will contain a concentration of 100U/mL 
in 3-mL cartridges of LY900014.
I8B-MC-ITSB (b) Clinical Protocol Page 30
LY900014During the l ead-in period, marketed 100 U/mL insulin lispro (Humalog) will be provided using 
open -label prefilled pens.
7.1.2. Medical Devices
The m edical  devices provi ded for use in the study  are disposable, prefilled insulin pens.  Patients, 
caregivers and invest igators will receive blinded pens in the blinded treatment arms and 
unblinded pens in the open label treatment arm .  LY900014 prefilled pens are new 
investigat ional co mbinat ion products .Theprefilled pen allows for dosing in half -unit 
increments and can dose between 0.[ADDRESS_451439] ion. 
This study  will also provi de pat ients with FDA approved BGmeters. The BG mete r used in this 
study  will bea meter that has received clearance from the FDA and m eets the ISO [ZIP_CODE]:[ADDRESS_451440] for blood glucose meters
.  
7.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to double -blind treatment or 
open l abeltreatm ent at Visit 4.  Assignment to treatment groups will be determined by a 
computer -generated random sequence using an interactive web -response system (IWRS).  
Patients will  be randomized to double -
blind LY900014, double -blind Humal og,or open -label 
LY900014+20 in a 2:2:1ratio.  Stratificat ion will be by [CONTACT_1606] , HbA1c stratum  (≤8.0%, >8. 0%)
based on HbA1c measured at Visit 1 ,type of basal insulin at randomizati on (insulin glargine , 
detemir ,or degl udec) ,and age group (1 to<12,
12to<18 y ears).
The IWRS will be used to assign all IP (blinded and open- label) during the study .  Site personnel 
will confirm that they  have l ocated the correct prefilled pens by [CONTACT_45342] a confirmat ion number 
found on the prefilled pen carton into the IWRS.
7.2.1. Selection and Timing of Doses
[IP_ADDRESS]. Target Glucose Values for Titration of Insulin Therapy
The overall glycemic control goals for all pat ients enro lled in the study  are similar to those 
recommended by  [CONTACT_362292] c and Ado lescent Diabetes (DiMeglio et 
al. 201 8).  The g lucose target val ues shown in Table ITSB. 4are suggested guidelines that are 
requi red in order to achieve a nHbA1c goal  of <7.0% (53 mmo l/mol)and m ay be used to
determin einsulin dose titration.Targets may be i ndividualized, aiming for the l owest achi evable 
HbA1c wit hout undue exposure to severe hypoglycemia .  
A higher HbA1c goal (in most cases <  
7.5% (58 mmo l/mol) may be appropri ate in y ounger children who are unable to articulate 
symptoms of hypoglycemia.  
I8B-MC-ITSB (b) Clinical Protocol Page 31
LY900014Table ITSB. 4. Glucose Target Values
Target Range
Before meals 70 -130 mg/dL
(4.0-7.0 mmol/L)
Postprandial ( 1hr) 90 to 180 mg/dL
(5.0 to 10.0 mmol/L)
Bedtime 80-140 mg/dL
(4.4-
7.8 mmol/L)
HbA1c <7.0%(53mmol/mol)
Abbreviations:  HbA1c = hemoglobin A1c; w/out = without.   
Source: DiMeglio et al. 2018
[IP_ADDRESS]. Timing of Doses
Marketed insulin lispro ( Humalog )will be dispensed to all patients for use throughout the lead -in 
period. At randomization (Visit 4), patients study  treatm ent (LY900014 or Humalog ) starting 
dose may be initiated unit for unit however, investigators may consider reducing the prandial or 
correcti on doses based on patient’s overall glycemic status or other considerat ions known to 
investigator in ord er to reduce risk of postprandi al hypo glycemia .  
In the blinded treatm ent 
groups, LY900014 and Hum alogwill be administered immediately prior to each meal (0- 2 
minutes) . The LY900014 +20open l abel treatm ent group willadminister the dose up to [ADDRESS_451441] igator as determined by 
[CONTACT_362293] (blinded LY900014 orblinded Humal og; 0-2 minutes before or open -
label LY900014; up to 20 minutes after the start of the meal).  An occasio nal change in the 
timing of inject ion may be warranted due to individual circumstances and will not be considered 
a protocol vio lation unless deemed by [CONTACT_362294].
The patient’s basal insulin during the study  can be dosed at any  time and shoul d be taken at 
approximately  the same t imeeach day . Patients shoul d use the same basal insulin regimen (type 
and dosing frequency) throughout the study .  
Patients will  record allinsulin doses in the study  
diaryas instructed.
Patients will  be requi red to collect glucose values atleast 4 times (before meals and bedt ime) 
each day  using the BG meter provi ded or a personal CGM/FGM that is approved for non -
adjunctive use ; i.e. resul ts may be used to make insulin dosing decisi onsper thei r local country  
regul ations (Secti on9.1.5 ).  The investigator will review glucose values at office and telephone 
visits in order to determine any insulin dose adjustments.  Once BG targets are achieved and 
basal and prandial dose titr ation has been optimized, daily  4-point glucose testing frequency and 
timing m ay be adj usted at the invest igator’s discretio n in consultat ion with patient and 
caregiver . Effort should be made to reach the BG target recommendations provi ded 
(Table ITSB. 4).  
I8B-MC-ITSB (b) Clinical Protocol Page 32
LY9000147.[IP_ADDRESS]. Basal Insulin Adjustment
Basal insulin shoul d be adjusted during the lead- in period by [CONTACT_362295],individual pat ient needs or to facilitate optimal prandial 
insulin dosing toachieve or maintain glucose targets wi th an emphasis on the pre -breakfast BG.
Adjustment of basal  insulin doses m ay cont inue throughout the study  treatm ent peri od in or der 
to achieve or maintain glycemic targets and for safety reasons .  The prescribed basal insulin 
dose i s determined by, and the responsibilit y of, the invest igator in consultat ion with the patient 
or caregiver .Addit ional discussi on between visits may be requi red to enable the patient to reach 
glycemic targets and will be determined by [CONTACT_093].  
[IP_ADDRESS].2. Prandial Insulin Adjustment
Prandial insulin should be titrated during the treatment period in order to reach optimal dosing 
and achieve glucose targets .  Reasonable efforts should be made to achieve these targets during 
the first [ADDRESS_451442] igator .  
Addit ional postprandial glucose monitoring may  be consi dered during the days following 
transi tion to study  insulin at the discretion o f the investigator. Patients may  use thei r usual  
correcti on factor (CF) or insulin sensit ivity factor (ISF) to determine dose needed to correct a 
high BG to their target level. This m ay be in addit ion to thei r meal-related dose.  Investigators 
shoul d instruct pati ents and ca regivers of the potenti al for hypoglycemia if prandial insulin is 
given to ofrequently to a previous IP injection (insulin stacking ).  
Patients m ay determine thei r prandial  IP dose by  [CONTACT_362296], 
but they  shoul dmaintain t he same dosing method throughout the study .  
Pattern adjustment: The patient is prescribed a fixed dose or dose range of insulin for each 
meal .  
The fixed insulin dose may be individualized for each meal.
Carbohydrate counting: The patient performs carb ohydrate coun ting for prandial insulin 
dosing ;prandial  insulin dose i s based upon the estimated carbohydrate content of the 
meal (as unit ofinsulin per grams carbohydrate) .  
Based on the patient’s individual needs and glucose values , the insulin to carbohydrate ratio and 
CFshoul d be assessed and adjusted as often as needed in order to meet the target glucose values
described in Table ITSB. 4.  Postprandial SMBG values from 7-point SMBG profiles should also 
be evaluated for optimizat ion of prandial insulin dosing.
For pati ents who are using pattern adjustment, the prandial insulin dose should be assessed and
adjusted as often as needed in order t o achieve glucose targets .  
I8B-MC-ITSB (b) Clinical Protocol Page 33
LY900014Patients shoul d attem pt to eat 3meals (morning, mid- day, and evening) wi th at least [ADDRESS_451443] yle changes (such as exercise, illness, or stressful 
events) that may affect the insulin dose n eeded .  
7.3. Blinding
This is a double -blind study; both treatment arms, LY900014 and Humal og, will  be administere d 
immediately  prior to each meal  in a doubl e-blind manner.  Investigators, patients, and study  site 
personnel will be blinded to assigned insulin regimen throughout the study . Athird open -label 
treatm ent group consi sts of LY900014 administered up to 20 minutes after the start of a meal 
(LY900014+20).  To preserve the blinding of the study , the Lilly  study  team  will remain blinded 
throughout the study; only a minimum number of Lilly personnel will see the randomization 
table and treatm ent assignments before the study  is com plete.
Emergency  unblinding for AEs m ay be perform ed through the IWRS, which may suppl ement or 
take the place of emergency  codes generated by  a com puter drug -labeling system. This opti on 
may be used ONLY if the patient’s well -being requires knowledge of the patient’s treatment 
assignment. Unblinding events are recorded and reported by [CONTACT_8784] .  
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted for medical management of the event.  The 
patient safet y must always be the first considerat ion inmaking such a determinat ion.  If a 
patient’s treatment assignment is unblinded, Lilly must be notified immediately.   
If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rati onale in the patient notes and notify Lilly as soon as 
possible .  
7.4. Dosage Modification
See Secti on 7.2.1 .  
7.5. Preparation/Handling/Storage/Acc ountability
The invest igator or his/her designee is responsible for confirming appropriate temperature 
condi tionshave been maintained during transit for all study  treatm entsreceived and that any 
discrepancies are reported and resolved before use of the s tudy treatm ent.  
Only patients enrolled in the study  may receive IP, and only authorized site staff may supply or 
administer study  treatm ent.  All  study  treatm ents shoul d be stored in an environmentally 
controlled and mo nitored (manual or automated) area in accordance with the labeled storage 
condi tions, with access limited to the invest igator and authorized site staff.
All insulin products must be stored at the invest igative site under refrigerated condit ions 
(between 2°C and8°C) in a l ocked and secure place.  Insulin must not be frozen.
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451444] 
maintenance (such as receipt, reconciliat ion, and final disposit ion records).
7.6. Treatment Compliance
The invest igator or designee will assess patientcompliance at each visit, based o n a review of the 
patient’s glycemic control using available glucose values and HbA1c results , adherence to the 
visit and treatment schedule, and complet ion of thestudy  diary.  Patients who are deemed 
nonco mpliant will receive addit ional diabetes educatio n and training, as required, and the 
importance of co mpliance with the protocol will be reinforced. Patients who, in the opi[INVESTIGATOR_3078] n of 
the invest igator, are deemed consistent ly noncom pliant m ay be discont inued fro m IP or fro m the 
study . No specific study  data will be co llected for analysis of treatment compliance.
7.7. Concomitant Therapy
All conco mitant therapi [INVESTIGATOR_362268] . Those listed in the exclusio n criteria cannot be used.  The subject should be encouraged 
to report any  new conco mitant m edicati ons af ter ini tiating the medicat ion.  Pl ease check with the 
study  team  if you have any concerns or questions about a medicat ion the subject is taking.  
Prohibited and restricted concomitant medicat ions are listed below.  
The fo llowing concomitant medicat ions are NOT allowed at any  timeduring the study  
 Insulin glargine U -300, insulin degludec U -200, 
 Afrezza®(inhaled insulin) 
 premixed human or analog insulin
 Any noninsulin diabetes treatment therapy
The fo llowing concomitant medicat ions ARE allowed for up to a total of 14 days during the 
study
 Regular human insulin , NPH or a nonstudy rapid analog insulin
 Systemic glucocorti costeroi d 
o Including ;intravenous , intram uscular, SC, or oral
7.8. Treatment after t he End of the Study
LY900014 will not be made available to patients after conclusion o f the study .  Rapi d-acting 
insulin analogs are available in all countries for use as prandial insulin.
After di scontinuat ion of IP at the end of the treatment period or e arlier, it is recommended that 
patients return to their pre -study  basal and prandial insulin; however, the cho ice of insulin 
therapy  shoul d be made by  [CONTACT_362297] .  
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451445] ment throughout the fo llow-up peri od in order to m aintain glycemic control.
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451446] ion.  Thi s study  includes elements to 
minimize missing data.  Rando mized patients who are discont inued fr om IP before study  
completion are encouraged to remain in the study  for continued mo nitoring.  For patients who 
remain in the study  after early discont inuat ion of IP, both efficacy (including HbA1c) and safet y 
data will be co llected at scheduled visits.  The difference between stoppi[INVESTIGATOR_362269], and patients will be 
encouraged to continue in the study  even if they  stop study  drug.  In addi tion, study  site 
investigators will be trained on the importance of complete data collection, with addit ional 
re-education of sites and patients as necessary .  
8.1.1. Permanent Discontinuation from Study Treatment
Possible r easons leading to permanent discontinuatio n of IPare:
Subject Decision
o The patient/or the pati ent’s designee, for example, parents or legal 
guardi an requests to discontinue IP.
The invest igator may decide that the patient should stop IP.  If this decisio n is 
made because of an AE, SAE, or a clinically significant laboratory  value, the 
study  drug i s discont inued for that patient and appropriate measures are to be 
taken.  Lilly or its designee is to be alerted.
The patient beco mes pregnant.
An invest igator, study site personnel performing assessments, or patient is 
unblinded, the patient m ust di scont inue IP .  
The patient, for any  reason, requi res treatm ent wi th another therapeuti c regimen 
or therapeutic agent that has been demo nstrated to be effective for treatment of 
the study  indicati onwith the except ion of those described in Section 7.7.  
Discontinuati on from IP shoul d occur prior to introducti on of  the new agent.
Frequent u se of prohibited conco mitant m edicat ion, see Section 7.7.
Patient has not taken IP for more than 14 consecutive days.
Patient discont inuat ion is reco mmended by [CONTACT_1363].
Discontinuation due to a hepatic event or liver test abnormality .  Patients who 
are discont inued fro m the IPdue to a hepat ic event or liver test abnormalit y 
shoul d have addi tional hepatic safet y data collected via case report form (CRF).
I8B-MC-ITSB (b) Clinical Protocol Page 37
LY900014Discontinuati on of  the IPfor abnormal li ver tests should be considered by [CONTACT_32845] a patient meets 1 of the fo llowing condi tions af ter consul tation wi th the 
Lilly -designated m edical m onitor:
ALT or AST > 8×ULN
ALT or AST > 5×ULN for more than 2 weeks
ALT or AST > 3×ULN and total bilirubin level (TBL) > 2×ULN or 
internat ional norm alized rati o>1.5
ALT or AST > 3×ULN with the appearance of fatigue, nausea, vo miting, 
right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
alkaline phosphatase ( ALP ) >3×ULN
ALP >
2.5×ULN and TBL > 2×ULN
ALP >2.5×ULN wi th the appearance of fat igue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
8.1.2. Temporary Discontinuation from Study Treatment
Patients who tem porarily discontinue the IP m ay 
have used non- study  insulins.  The patient will 
be allowed to resum e IP if they havenot taken IP for up to a total of [ADDRESS_451447] igator and the sponsor clinical research physician (CRP )agree that
it is medically appropriate to continue, the invest igator m ust obtain documented approval from 
the sponsor CRP to allow the inadvertent ly enrolled patientto con tinue in the s tudy with or 
without treatm ent wi th IP. Safet y follow-up is as outlined in Sect ion 2(Schedule of Act ivities
Table ITSB .1), Section 9.2(Adverse Events), and Section 9.4(Safet y) of the protocol.
8.2. Discontinuation from the Study
Patients will  be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical study  involving an IPor enrollment in any 
other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and g ood clinical  
practi ce
I8B-MC-ITSB (b) Clinical Protocol Page 38
LY900014investi gator decisio n
othe invest igator decides that the patient should be discontinued from the 
study
oif the pat ient, for any  reason, requi res treatm ent with another therapeutic 
agent that has been demonstrated to be effect ive for treatment of the study  
indicat ion, discont inuat ion from the study  occurs pri or to introducti on of  
the new agent
patient decision
othe patientor the patient’s designee, for example, parents or legal guardian
requests to be withdrawn fro m the study
Patients discont inuing fro m the study  prem aturely for any  reason shoul d com plete EDand other 
safet y follow
-up per Secti on 2(Schedule of Activit iesTable ITSB .1.), Section 9.2(Adverse 
Events) ,and Section 9.4(Safet y) of this protocol .
8.3. Lost to Follow -Up
A patientwill be considered lost to fo llow
-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451448] results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy and Safety Assessments
9.1.1. Primary Efficacy Assessments
The primary  efficacy  measure is the change from baseline to Week 26 in HbA1c.
9.1.2. Secondary Efficacy Assessments
The fo llowing secondary  efficacy measures will be collected at the times shown in the Schedule 
of Activities (Secti on 2,Table ITSB .1).  
Prandial, basal, and total insulin dose s(units and uni ts/kg) and prandial/total  
insulin ratio
Proporti on of  patients wi th HbA1c<7.0% and <7.5%
SMBG 7-point profiles (fast ing, [ADDRESS_451449] evening meal, and bedtime)
o 1-hour PPG excursions
o within-and between -day glucose variabilit y measured by [CONTACT_362298] (SD)
.
9.1.3. Safety Assessments
Rate and incidence of hypoglycemia :
o docum ented post-dose
o docum ented
o severe
Adverse events
Laboratory  value assessments
Weight .
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451450] to diabetes mellitus.
9.1.5. Study Procedures
During this study ,the pati entor caregiver will be responsible for the following:
Every day
 Answering study diary questi ons f or all hypoglycemia events
 Obtain ingglucose value before meals and at bedtime
At least 3 days before all visits (telephone and office) 
 Recording daily  basal dose ,including date 
 Recording prandial dose s,including date and time
At least 3 days during the 2 weeks before Visit s 4, 10, and 15
 Collect ing3 separate 7-point SMBG profiles using the study  provi ded 
meter and record ing in study diary
[IP_ADDRESS]. Self-Monitored Blood Glucose
A study  BG meter will be provided to all pat ients who meet screening criteria and should be used 
to obtain all 7-poi nt SMBG values throughout the study .  Patients will be required to collect 
glucose values at least 4 times (before meals and bedtime) each day using the BG meter provided 
or a personal CGM/FGM that is approved for non -adjunctive use, ( i.e. results may  beused to 
make insulin dosing decisio ns)per thei r local country  regul ations (Section [IP_ADDRESS] ).
Patients who do not wear a personal CGM/FGM will use the study  provi ded BG meter; 
 to perform all 4- point and 7 -point glucose values,
 to record gl ucose values in their study  diary, and 
 to perform the glucose assessment for hy poglycemia events.  
These glucose values are used by  [CONTACT_17062] f or dose titration as well as to assess pat ient 
safet y during the study . Once BG targets are achieved and basal and prandial dose titration has 
been optimized, daily  4-point glucose testing frequency and timing may  be adjusted at the 
investigator’s discret ion (in consultat ion with patient and caregiver) to allow for individual 
patient needs and lifestyle changes. Missing values in SMBG profiles w ill not be considered 
protocol  deviat ions unless, in the opi[INVESTIGATOR_3078] n of the investigator, they  are excessive and reflect 
nonco mpliance wit h the protocol . Patients should be encouraged to eat 3 meals on the days that 
the 7-point SMBG is monitored. 
Patients shoul d perform  SMBG with the study  provided BG meter whenever hypoglycemia is 
experienced or suspected (with or wi thout symptoms), when there is perceived increased risk as 
related to changes in dietary  intake, physical activity ,or inadvertent or aty pi[INVESTIGATOR_362270] .  
Patients who wear personal CGM/FGM should use the study  provi ded BG m eter to confirm 
hypoglycemia symptom s or a CGM val ue ≤ 70mg/dL (3.9 mmo l/L).
I8B-MC-ITSB (b) Clinical Protocol Page 41
LY900014Collection Schedule for Glucose Values
Glucose Value How Many When
4-point
(SMBG or 
CGM /FGM )Daily Daily
7-point
(SMBG)9total 3×during the 2 week sprior to Visits 4, 10, and 15.
Glucose Values
Timing 4-Point (SMBG or CGM/FGM) 7-Point (SMBG)
Fasting (pr emorning meal ) X X
[ADDRESS_451451] evening meal X
Bedtime X X
[IP_ADDRESS]. Use of Personal CGM or FGM
Patients will be allowed to use their personal CGM or FGM .  Patients who choose to wear their 
personal CGM/FGM device should make every attempt to wear i t throughout the entire study .  
Personal CGM/FGM use (y es/no) will  be recorded at Visit 4 . 
Patients who wear a personal CGM/FGM: 
 will co llect [ADDRESS_451452] the discret ion to 
downl oad gl ucose data from a personal CGM/FGM device as per usual practice
 shoul d perform  7-point glucose values by  [CONTACT_362299] -provi ded BG meter, 
and
 shoul d use the study -provi ded BG meter to confirm hypoglycemia symptoms or a 
CGM value ≤ 70m g/dL (3.9 mmo l/L). 
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate healt hcare opti on, 
AEs that are serious or otherwise medically important, considered rel ated to the IPor the study , 
or that caused the patient to discont inue the IPbefore complet ing the study .  The patient should 
be followed unt il the event resolves, stabilizes wit h appropriate diagnostic evaluat ion, or i s 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451453].
After the informed consent form ( ICF) is signed, study  site personnel  will record vi a electroni c 
data entry  the occurrence and nature of each pat ient’s preexist ing condit ions, including clinically  
significant si gns and symptom s of the disease under treatment in the study .  In addit ion, site 
perso nnel will record any change in the condit ion(s) and any new condit ions as AEs . 
Invest igators should record their assessment of the potential relatedness of each AE to protocol 
procedure and/or IP, via electronic data entry .  
The invest igator will interpr et and docum ent whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y”means that there is a cause -and-effect rel ationship between the IP, 
study  device and/or study  procedure ,and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s IPis discont inued as a result of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via electroni c data entry , clarifying, if possible, the circumstances leading to any  
dosagemodificat ions or di scont inuat ions of treatment .  
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1of the f ollowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_18543],but may  jeopardi ze the pati ent or may  requi re 
intervent ion to prevent 1of the other outcomes listed in the definit ion above.   
Examples of such medical events include allergic bronchospasm requiring 
intensive treatm ent in an emergency  room  or at home, blo od dyscrasias or 
convulsio ns that do not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency  or drug abuse
I8B-MC-ITSB (b) Clinical Protocol Page 43
LY900014when a condit ion related to the prefilled pen necessitates medical or surgical 
intervent ion to preclude either permanent impai rment of  a body  functi on or 
perm anent dam age to a body  structure, the seri ous outcom e of “requi red 
intervent ion” will be assigned
severe hypoglycemia events:  epi[INVESTIGATOR_362271]9.4.[ADDRESS_451454] igator 
awareness o f the event vi a a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.
Pregnancy ( during maternal exposure to IP) does not meet the definit ion of an AE.  However, to 
fulfill regulatory  requi rements ,any maternal pregnancy shoul d be reported following the SAE 
process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patient disposit ion CRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any  time after a subject has 
been discharged from the study , and he or she considers the event reasonably possibly related to 
the study  treatm ent or study  parti cipati on, the investi gator m ust prom ptly notify Lilly.
[IP_ADDRESS]. Suspected Unexpected Serious A dverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IPor procedure.  [LOCATION_002] 21 CFR 
312.32 ,European Unio n Clinical Trial Directive 2001/20/EC ,and the associated detailed 
guidances or nati onal regulatory  requi rements in parti cipat ing countries require the reporting of 
S[LOCATION_003]Rs. Lilly has procedures that will be fo llowed for the ident ificat ion,recording ,and 
expedited reporting of S[LOCATION_003]Rs that are consistent with global regulat ions and the associated 
detailed guidances.
9.2.2. Complaint Handling
Lilly co llects product complaints on IPsand drug delivery  systems used in clinical studies in
order to ensure the safet y of study  partici pants, m onitor qualit y, and to facili tate process and
product improvements.
Patients will be instructed to contact [CONTACT_81129] a
complaint or probl em wi th the IPor drug delivery system so that the si tuation can be assessed.
I8B-MC-ITSB (b) Clinical Protocol Page 44
LY900014Com plaint s must be reported by  [CONTACT_157720] 24 hours of notificat ion to the clinical 
site/study  personnel or within 24 hours of study /site personnel beco ming aware of a 
product issue, regardless of the availabilit y of the com plaint sample .  
Retai n the IP under appropriate storage condit ions, if available or when obtained, until 
instructed to return it to Lilly .  
Product complaints for non -Lilly  products (including conco mitant drugs) that do not have 
a Lilly  Product Batch or Control number a re reported directly to the m anufacturer per 
product label .
Follow the instructi ons outlined in the Product Complaint Form for other reporting 
requi rements.
9.3. Treatment of Overdose
Excess insulin administration may result in hypoglycemia.  Refer to the IB fo r LY900014 and 
product label for Hum alog.
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451455] ivity,
or inadvertent or aty pi[INVESTIGATOR_362272].  All pat ients will be instructed to treat a BG level 
≤70mg/dL (3.9 mmo l/L) as hypoglycemia.
If a hypoglycemia event is suspected, patient sshoul d measure the BG value using the study  
provi ded m eter and record the BG value in the diary , any associ ated symptom s, and the 
treatm ent administered in the study  diary .  The patient shoul d contact [CONTACT_362300] .  All  
hypoglycemia events (severe and non -severe) m ust be reported on the hy poglycemia electroni c 
case report form(eCRF ); see below and Section 9.4.[ADDRESS_451456] be reported as SAEs on the AE eCRF page and on the SAE eCRF page.  Reports of 
hypoglycemia will be classified by [CONTACT_1694] “severe” or “no t severe” based upon data 
collected in the patient diary and in consultat ion with the pati ent.  Epi[INVESTIGATOR_362273].  
Hypoglycemia will be described using the following definit ions:
Documented Glucose Alert ; BG ≤70 mg/dL (3.9 mmol/L ):  
oDocumented symptomatic hypoglycemia :  an event with ty pi[INVESTIGATOR_157696] s of 
hypoglycemia .  
oDocumented asymptomatic hypoglycemia :  an event without ty pi[INVESTIGATOR_157696] s of 
hypoglycemia .  
oDocumented unspecified hypoglycemia :  with no informat ion about symptoms of 
hypoglycemia available (this has also been called unclassifiable hypoglycemia).
Documented Clinically Significant Hypoglycemia with similar criteri aas above ,
except for threshold BG<54 mg/dL (3.0 mmol/L)
oDocumented symptomatic hypoglycemia
oDocumented asymptomatic hypoglycemia
oDocumented unspecified hypoglycemia
Severe Hypoglycemia:  during these epi[INVESTIGATOR_1841], patients have an altered mental status and 
cannot assist in their own care, m ay be semiconscious or unconscious, or experience 
coma with or wi thout sei zures, and requi reassistance of another person to actively  
administer carbohydrate, glucagon, or other resuscitat ive act ions.  B lood gl ucose
measurements may  not be available during such an event, but neurological recovery  
attributable to the restoration of BG concentration to normal is considered sufficient 
evidence that the event was induced by a low BG concentration 
(BG≤70mg/dL [3.9mmo l/L]).  
oNote :  Young children will frequent ly require assistance wi th treatm ent of  
hypoglycemia but are not experiencing signs o f altered mental  status or cognitive 
impair ment .  Final determinat ion shoul d be made by  [CONTACT_362301] a 
severe hypoglycemia event meet ing the descript ion provi ded above.
Other Hypoglycemia :
I8B-MC-ITSB (b) Clinical Protocol Page 46
LY900014oNocturnal hypoglycemia:   any documented hypoglycemic event (including severe 
hypoglycemia) that occurs between bedt ime and waking.  
oProbable symptomatic hypoglycemia:   an event during which symptoms are 
present, but BG measurement was not reported .  
oOverall (or total) hypoglycemia :  this category  combines all cases of hypoglycemia 
(documented hypoglycemia andprobable symptom atichypoglycemia, including 
severe hypoglycemia) excluding the events ofrelative hy poglycemia .  Nocturnal  and 
severe hypoglycemia are special cases of documented or probable hypoglycemia.  If 
an event of hypoglycemia falls into mult iple subcategories, the event is only counted 
once in this category .
9.4.2. Severe Hypoglycemia
Young c hildren ,because of their age ,will frequently  require assistance wit h treatment of 
hypoglycemia ,but are not experiencing signs of changes in mental statu s. The f inal 
determinat ion of a hypoglycemic event as an epi[INVESTIGATOR_362274] a bove i s 
made by [CONTACT_362302] ( that 
is,altered m ental  status or cogni tive impairment) and is not predicated on the report of a child 
simply having received assistance .  
9.4.3. Vital Signs , Height, and Weight
For each patient, vital sign s, height , and weightmeasurements should be conducted according to 
the Schedule of Act ivities (Secti on 2, Table ITSB . 1) and fo llowing the study -specific 
recommendat ions.
Any clinically  significant findings from vital sign measurement that result in a diagnosis and that 
occur after the patient receives the first dose of study  treatm ent shoul d be reported to Lilly  or its 
designee as an AE via electronic data entry .
9.4.4. Laboratory Tests
For each patient, laboratory  tests detailed in Appendix [ADDRESS_451457] ivities (Secti on 2, Table ITSB . 1).  
With the exception o f laboratory  test resul ts that may  unblind the study , Lilly or its desi gnee will 
provi de the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor i s used for the clinical trial.  
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the patientreceives the first dose of IPshoul d be reported to Lilly  or its designee as an AE
via electronic data entry .
9.4.5. Immunogenicity Assessments
Blood sam ples f or immunogenicit y testing will  be collected for the assessment of ant i
-insulin 
lispro antibodies as specified in the Schedule of Acti vities (Secti on 2,Table ITSB . 1).  This 
assessment will be performed using a validated assay  at a l aboratory  approved by [CONTACT_456].  
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451458] patient visit or for a shorter 
period if local  regulat ions and ethical review boards (ERBs) allow, at a facilit y selected by  [CONTACT_103].  The duration allows the sponsor to respond to future regulatory  requests rel ated to 
LY900014.  Any samples remaining after [ADDRESS_451459] (an advisory  group for thi s study  
formed to protect the integrity  of data; refer to Interim Analyses section [Secti on 10.3.8 ]) can 
conduct addit ional analyses of the safet y data.
Thedata and safet y monitoring committee (DMC) consist ing of pediatri c experienced members 
external to the study  team  will review safety resul ts at least once during the study .  The DMC 
comprises those individuals responsible for the evaluat ion and interpretation of the results fro m 
the interim analysis.  The DMC for this study  will be conducted as an independent DMC.  
Therefore, the me mbers of the DMC are external to Lilly .  Further details pertaining to the DMC 
activit ies may be found in the DMC charter.  Unblinding details are specified in the unblinding 
plan sect ion of the statistical analysis plan (SAP).  
Only the D MC is authorized to eval uate unblinded interim safet y analyses.  Study  sites will 
receive informat ion about interim results ONLY if they  need to know for the safet y of their 
patients.
[IP_ADDRESS]. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3×ULN, ALP ≥ 2×ULN, or elevated TBL ≥2×ULN, 
liver testi ng (Appendix 4 ) shoul d be repeated wi thin [ADDRESS_451460], TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels .  
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the CRF if 1 or more of the fo llowing condi tions 
occur: 
elevation of serum  ALT to ≥5×ULN on 2 or more consecut ive blood tests
elevated serum TBL to ≥2×ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALPto ≥
2×ULN on 2 or more consecut ive blood t ests
patient discont inued fro m treatm ent due to a hepatic event or abnormalit y of 
liver tests
I8B-MC-ITSB (b) Clinical Protocol Page 48
LY900014hepatic event considered to be a SAE .
9.5. Pharmacokinetics
Not a pplicable .
9.6. Pharmacodynamics
Not applicable .
9.7. Pharmacogenomics
Not applicable .
9.8. Health Economics
Not applicable .
I8B-MC-ITSB (b) Clinical Protocol Page 49
LY90001410.Statistical Considerations
10.1. Sample Size Determination
Approximately  708 patients will be rando mized in order that 600 patients complete the study  
through the primary endpoint at Week 26.
Patients will  be randomized in a 2:2:1 ratio to double -blind LY900014 dosed 0 to 2 minutes 
before m eals, double -blind Humal ogdosed 0 to 2 minutes before meals, or open -label 
LY900014 dosed up to 20 minutes after the start of a meal. Stratificat ion will be by [CONTACT_1606] , 
HbA1c stratum ( ≤8.0%, >8 .0%), ty pe of basal insulin (insulin glargine, insulin detemir ,or 
insulin degludec) ,and age group (1 to<12years , 12to<18years).  
Assuming a NIM of 0.4%, no true difference between treatment groups and a nSD of 1.1%, 240 
completers for each double -blind treatment group will provide greater than 95% power to show 
noninferiorit y between LY900014 and Hum alogusing the upper limit of a 2
-sided 95% CI 
(LY900014 −Humal og).  This sample size also has more than 80% power to show noninferiorit y 
between LY900014 and Humal ogusing a 0.3% NIM at 26 weeks.  
With the assumpt iona difference no larger than 0.07% between treatment groups and a SD of 
1.1% , 240 completers of double -blind Humal ogdosed 0 to 2 minutes before meals and 120 
completers of open -labelLY900014 dosed up to 20 minutes after the start of a meal will provide 
approximately  
76% power to show noninferiorit y between open -label LY900014 +20and double -
blind Hum alogusing a NIM of 0.4% .
.
Assuming a 15% dropout rate during 26 weeks of treatment, approximately 708 pat ients (283 
patients in each double -blind treatment group and 142 patients in the open -label treatm ent group) 
will need to be randomized.
10.2. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Populat ion Description
Entered All patients who give informed consent.
Randomized All patients who are randomly assigned to study treatment at Visit 4.  Treatment group will 
be defined on the basis of the treatment the patients are assigned.
Safety All randomized patients who receive at least [ADDRESS_451461] (IP).Treatment group will be defined on the basis of the treatment the patients are 
assigned.
Completer Patients included in the randomized population w ho have completed Week [ADDRESS_451462] the primary objective . 
Treatment group will be defined on the basis of the treatment the patie nts actually receive.
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451463] ificat ion for making the change, will be described in the 
SAP or the clinical study  report (CSR).  Addi tional exploratory  analyses of data will be 
conducted, as deemed appropriate.
The primary  analysis is for the treatment period through Week 26.
Efficacy analyses will be conducted on all rando mized patients according to the treatm ent the 
patients are assign ed. The analyses for the primary and gated objectives will be performed for 
the efficacy  estimand, including data collected prior to permanent discontinuat ion of IP and for 
the ITT estimand, including all data collected regardless of IP use .  The primary endpoint will 
also be analyzed using the PP and Completer populat ions.
Unless otherwise specified, the efficacy analyses for other secondary  object ives and exploratory 
objectives will be performed for the efficacy est imand.  When change fro m baseline is included 
as a response variable of analysis models, the patient will be i ncluded in the analysis only if a 
baseline and at least [ADDRESS_451464] treatm ent m ay be perform ed as needed.  Analyses of safet y laboratory  
measurements will be performed on all data during the planned treatment period regardless of IP 
use.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha l evel of 
0.05, and CIs will be calculated at 95%, [ADDRESS_451465] non -missing measurement at or before the rando mizat ion 
visit (Visi t 4), unless otherwise specified .  
A restricted maximum likelihood -based, mixed -effect m odel repeated -measure (MMRM) 
analysis will be used to analyze continuous longitudinal variables.  All the longitudinal 
observat ions at each scheduled postbaseline visit will be included in the analys is.  The model for 
I8B-MC-ITSB (b) Clinical Protocol Page 51
LY900014the analysis o f the primary efficacy  endpoint of change from baseline in HbA1c will include the 
fixed class effects of treatment, strata (pooled country , type of  basal  insulin ,and age group ), 
visit, and treatment -by-visit interaction, a s well as the continuous, fixed covariate of baseline 
value.  For analyses of variables other than HbA1c, the HbA1c stratum ( ≤8.0%, >8.0 %) will be 
included in the model.  An unstructured covariance structure will be used to model the 
within-patient errors.   Significance tests will be based on least-squares (LS) means and Ty peIII 
tests.  SAS PROC MIXED will be used to perform the analysis.  If this analysis fails to 
converge, the fo llowing covariance structures will be tested ,in order:
Toeplitz with hetero geneit y
Autoregressive with heterogeneit y
Com pound symmetry  with heterogeneous variances
Toeplitz
Autoregressive
Com pound symmetry  without heterogeneous variances .
The first covariance structure that converges will be used.  The Kenward -Roger approximat ion 
will be used to estimate deno minator degrees of freedom.  
An analysis o f covari ance (ANCOVA) will also be used to analyze continuous variables.  The 
model for the change fro m baseline to the Week 26 HbA1c endpoint will include treatment and 
strata (pooled country , type of basal insulin ,and age group ) as fixed effects and baseline as a 
covari ate.  Unl ess otherwi se stated, missing endpoints will be imputed using the
last-observation -carried -forward (LOCF) approach, using only  postbaseline data.  For analyses 
of variables other than HbA1c, the HbA1c stratum ( ≤8.0%, >8.0%) will be included in the 
model.
For continuous measures, summary statist ics will include sample si ze, mean, SD, m edian, and 
minimum and maximum for both the actual and the change fro m baseline measurements.  The 
LS m eans and standard errors derived from the analysis models will also be displayed for the 
change from baseline measurements.  Treatment com parisons will be displayed showing the 
treatm ent difference LS means and the 95% CIs for the treatment differences alo ng with the 
p-values for the treatment comparisons.
For categorical measures, summary  stati stics will include sample size, frequency, and 
percentages.  Fisher’s exact test or Pearson’s chi -square test will be used for treatment 
comparisons.  
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
A detailed description o f patient di sposi tion will be provi ded.  Frequency  counts and percentages 
of all pat ients entered, randomized, complet ing, and/or discontinuing fro m the study  will be 
presented for each treatment group.  Reasons for discontinuation fro m study  treatm ent and from  
I8B-MC-ITSB (b) Clinical Protocol Page 52
LY900014the study  during the treatm ent peri od will be summarized and compared b etween treatm ent 
groups using Fisher’s exact tests .  
[IP_ADDRESS]. Patient Characteristics
Standard baseline characterist ics of age, age group (Age Group 1 :  1 to <12, 12 to18 years and
Age Group 2 :  1 to <6, 6 to <12, 12 to <18 y ears), sex, ethnicit y, race, height, wei ght, and body 
mass index ( BMI )will be summarized for all randomized pat ients.  Summary statist ics will 
include sample size, mean, SD, median, minimum and maximum for continuous measures and 
sample size, frequency , and perc ent for categori cal measures.  Comparisons between treatment 
groups will be performed using Fisher’s exact test or Pearson’s chi -square test for categorical 
data and an analysis of variance with treatment in the model for continuous data for all pat ients. 
Baseline diabetes characterist ics will be summarized in a similar manner.
Preexist ing condit ions will be summarized by  [CONTACT_362303]  (PT) wi thin 
system  organ cl ass (SOC). No p -values will be reported.
[IP_ADDRESS]. Concomitant Therapy
Concomitant medicat ions used during the treatment period will be summarized and compared 
between treatment groups using Fisher’s exact test. The type of insulin therapy at study entry 
will be co mpared between treatment groups using Fisher’s exact tests .  
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  object ive of this study  is to test the hypothesis that LY900014 is noninferior to 
Hum alogon glycemic control (NIM=0.4% for HbA1c) in pat ients 1 to <18 years of age with 
T1D, when administered as prandial ins ulin (0 to 2 minutes prior to the meal), in combinat ion 
with basal insulin for 26 weeks.  There will be 2 primary  analysis methods, each tested at the full 
significance l evel of 0.05 .  
For the US FDA submission (using the ITT estimand), the missing endpo ints will be imputed by  
[CONTACT_362278]. The reference for each treatment group is fro m the retrieved 
dropout patients who discont inue IP buthave the measurement at the primary endpo int in the 
same treatment group . If there isonly a limi ted number of patients in the reference group that 
leads to a failure in performing the proposed mult iple imputati on analysis such that the model 
cannot converge , or the number of records in the reference group is less than the number of 
records wi th missing data, the missing endpo ints will be imputed by  [CONTACT_25034]-level observed 
baseline value plus a noise ,assuming a washout of any  potenti al treatm ent effect (or “return to 
baseline”) .The noise fo llows a norm al distribut ion with the vari ability estimated fr om the 
“washout HbA1c data”. The “washout HbA1c data” will be derived by [CONTACT_362304] [ADDRESS_451466] 
between LY900014 and Humal ogfrom an ANCOVA.  The m odel for the change fro m baseline 
to the Week 26 HbA1c endpoint will include treatment and strata (pooled country , type of basal 
I8B-MC-ITSB (b) Clinical Protocol Page 53
LY900014insulin, and age group ) as fixed effects and baseline HbA1c as a cov ariate. The final est imates 
will be the co mbined est imates fro m at least [ADDRESS_451467] between LY900014 and Hum alogat Week 26 (Visit 15) f rom the MMRM analysis 
of change from baseline in HbA1c ,including data collected from all rando mized patients prior to 
perm anent discont inuat ion of IP through Week 26 (efficacy  estimand).  The analysis model and 
select ion of covariance structure aredescribed in Secti on10.3.1 .
For both primary  analysis approaches, LY900014 will be declared noninferior to Humalog if the 
upper limit of the 2
-sided 95% CI for the LS mean difference in the change from baseline in 
HbA1c for LY900014 minus Humal ogis below +0.4%.  In addit ion, the 95% CI for the 
treatm ent difference will be compared to an alternative NIM of +0.3%.  Bot h estimands will be 
tested at the full significance level of 0.05.  
[IP_ADDRESS].1. Sensitivity Analyses for Missing Data
A missing -not- at-random -based analysis will be performed for both the efficacy and ITT 
estimands to assess sensit ivity to departures fro m the missing -at-random (MAR) assumption . 
The ti ppi[INVESTIGATOR_362275] (Ratitch et 
al.2013).  The basic idea is to impute the missing values and add a value (delta) to the imputed 
values of the experimental group and perform an analysis for the primary endpo int on the 
delta-adjusted data set to see whether the conclusio n of the primary  analysis is overturned.  If 
not, a larger del ta is chosen and the process is repeated until the primary  resul t is overturned.  If 
the delta required to overturn the primary result is not a plausible departure from MAR, then the 
primary  resul t is robust to plausible departures from MAR.  Imputation under the noninferiorit y 
null method, in which delta equals the NIM, will be included as a special case o f the progressive 
stress test .  
For the ITT estimand, the imputation of missing data will be as described for the FDA primary 
analysis and ANCOVA on the change fro m baseline to Week 26 in HbA1c will be used.  
For the efficacy estimand, t he copy  reference approach will be used to impute missing data and 
the reference group will be the Hum alogtreatm ent group.  Im putati on will be for all lo ngitudinal 
visits.
[IP_ADDRESS].2. Additional Analyses for the Primary Endpoint
The primary  MMRM analysis m odel will be repeated using the PP and Completer populat ions to 
check the sensit ivity of the analysis.  If the conclusio n differs fro m that of all rando mized 
patients, the data and analyses will be further investigated.  
A secondary  analysis model for the efficacy e stimand will be an ANCOVA for HbA1c change 
from baseline to Week 26 (Vi sit 15), using the model described in Sect ion 10.3.1 .  Missing 
endpo ints will be imputed using the LOCF approach using postbaseline data only.  
[IP_ADDRESS]. Secondary Analyses
Following the successful claim o f the primary objective, the assessment of noninferiorit y 
between LY900014+20 and Hum alogand superiorit y betwee n LY900014 and Hum alogin 
I8B-MC-ITSB (b) Clinical Protocol Page 54
LY900014controlling HbA1c will usegatekeepi[INVESTIGATOR_63966] .The noninferiorit y between LY900014+[ADDRESS_451468] with the significant level o f 0.05 (from  the primary  object ive).  
Once the noninferiorit y is achieved, th e superi ority test between LY900014 and Hum alogwill be 
perform ed wi th the si gnificant l evel of 0.05 (from the gated noninferiorit y object ive).  Both the 
assessment swill be based on the analysis approaches used for the primary objective (ITT 
estimand for FDA submissio n and efficacy estimand for non -FDA submissions). 
HbA1c and change fro m baseline in HbA1c at all timepo ints will be analyzed by [CONTACT_362305] m odel used for the primary  analysis for the efficacy  estimand. The noninferiorit y in 
change from b aseline in HbA1c for LY900014+[ADDRESS_451469] imand.  
Treatment comparisons for the proportion of patients wi th HbA1c<7.0% and <7 .5% will be 
analyzed using a longitudinal logist ic regressio n with repeated m easurements conducted by  a 
generalized linear mixed model including independent variables of treatment, baseline HbA1c 
value, visit, baseline HbA1c by  [CONTACT_176260], and treatm ent by  [CONTACT_362306].  A n 
unstructured covariance structure will be used.  As a sensit ivity analysis, the proportion of 
patients wi th HbA1c<7.0% and <7.5% at Week 26 (Visit 15), im puted using LOCF, will be 
compared using a l ogistic regressio n model including treatm ent and baseline HbA1c value in the 
model.  
[IP_ADDRESS]. Tertiary/Exploratory Analyses
Continuous variables and the change from baseline for these variables will be analyzed either by 
[CONTACT_362307] [IP_ADDRESS] .  Categorical variables will be 
analyzed either by [CONTACT_338293] (for example, logist ic regressio n) or by  [CONTACT_3493]’s exact test or Pearson’s 
chi-square test.  Analysis details for the tertiary  endpo ints will be described in the SAP.
10.3.4. Safety Analyses
Safety measures will include AEs, hypoglycemia, vital signs and weight, treatment exposure, 
laboratory  measures, and ant ibodies to insulin lispro.  Analyses will be performed on data 
collected from rando mization through Visit [ADDRESS_451470] dose of IP or reported to worsen in severit y from 
baseline will be considered treatment -emergent AEs (TEAEs).  The Medical Dict ionary for 
Regulatory  Activities (MedDRA) lowest level term (LLT) will be used in the treatment -emergent 
assessment.  The maximum severit y for each LLT during the baseline period will be used as 
baseline severit y.
The SAEs, AEs reported as reason for discont inuatio n from the IP or st udy, and TEAEs will be 
summarized in tables using the MedDRA PT, sorted by  [CONTACT_362308]900014 treatment group.  The TEAEs will also be summarized by [CONTACT_362309].  For events that are specific to 
only 1 sex, the deno minator and computation of the percentage will include only pat ients from 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451471] 1 event for each ty pe of event 
will be summarized and co mpared between treatment groups using Fisher’s exact test.  
Hypoglycemia rates will be summarized for periods of 30 day s, 1 y ear, and 100 years (severe 
hypoglycemia only ).  The rate of severe hypoglycemia per 100 y ears will be com pared between 
treatm ent groups using the empi[INVESTIGATOR_362263] (details will be described in SAP).  For each of the 
other categories of hypoglycemia, the number of hypoglycemia events during a specific
periodafter randomizat ion (for example, Weeks 0 to 12 of treatment period) will be analyzed by 
[CONTACT_2329] a negat ive bino mial regressio n model.  The m odel will include treatment and age group as 
covari ates.  An offset defined as the log transformation of trea tment exposure in the specific 
period (day s)/365.25 days (or 30 day s) will be included in the model to estimate the rate of 
hypoglycemia per y ear (or per 30 days).  The proportion of patients with at least 1 hy poglycemic 
event in each category  during a spe cific peri od after randomizat ion will be analyzed using a 
logistic regressio n model including treatm ent and age group as covariates .  
Continuous safety  variables, as well as the change fro m baseline for these variables, will be 
analyzed by [CONTACT_362280].  For categorical variables, Fisher’s exact test or 
Pearson’s chi -square test will be used to compare treatment groups ,unless otherwise specified.
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
Not applicable.
10.3.6. Evaluation of Immunogenicity
The treatment -emergent anti -insulin lispro antibody (denoted as
treatm ent-emergent antidrug antibody [TEADA] throughout this document) is based on the 
change from baseline to postbaseline in the ant i-insulin lispro antibody level ( percent binding) . 
The TEADA can be sub- classified as either treatment -induced (not detected anti- insulin lispro 
antibody  at baseline) or treatment- boosted (detected anti -insulin ant ibody  at baseline):
treatm ent-induced response:  change from not detected anti- insulin lispro at baseline to 
postb aseline detected anti -insulin lispro and
treatm ent-boosted response:  change from detected anti -insulin lispro at baseline to 
postbaseline detected anti -insulin lispro antibody level ( percent binding) at least 157% of 
the baseline value.
The summary of TEA DA will  be provi ded b y treatment group. Fisher’s exact test will be used 
for the treatm ent com parison.
The rel ationship between the presence of TEADA and selected efficacy and safet y measures will 
also be evaluated. Analyses details will be documented in the SAP.
I8B-MC-ITSB (b) Clinical Protocol Page 56
LY90001410.3.7. Other Analyses
[IP_ADDRESS]. Subgroup Analyses
The fo llowing subgroups will be analyzed using the efficacy  estimand to evaluate consistency  of 
treatm ent effects on the primary  efficacy  measure if there are sufficient numbers of patients in 
each treatment by  [CONTACT_6496] (for example, 10%):
Age (Age Group 1 :  1 to<12, 12 to <18 y earsand Age Group 2 :  1 to <6, 6 to <12, 12 to 
<18 y ears)
HbA1c stratum ( ≤8.0%, >8. 0%)
Type of basal insulin at randomizat ion (insulin glargine, detemir ,or degl udec)
Sex (m ale or female)
BMI (<25, ≥25 kg/m 2and <30, ≥30 kg/m 2)
Durati on of  diabetes ( using the median as the cutoff )
Race
Ethnicit y
Country
Region
Prandial insulin dosing plan (carbohydrate counting, pattern adjust ment)
.
Analyses for HbA1c and change from baseline in HbA1c will be perform ed using an MMRM 
model that includes the sam e fixed effects given for the primary  analysis model plus factors of 
subgroup, [ADDRESS_451472] ion of treatment, visit,and subgroup.  The interaction of subgroup and 
treatm ent at the primary  endpoint (Week 26) will be evaluated to assess the treatment by  
[CONTACT_226418].  
Addit ional subgroup analyses may also be performed.
10.3.8. Interim Analyses
There will be no int erim analysis, but safet y will be m onitored by  a DMC.  A limited number of 
pre-identified individuals may gain access to the limited unblinded data for DMC review , as 
specified in the DMC charter .  Information that may unblind the study  during the analyses will 
not be reported to study  sites or the blinded study  team  until  the study  has been unblinded.
Unblinding details are specified in the unblinding plan sect ion of the SAP and the DMC charter
orin a separate unblinding plan document .
I8B-MC-ITSB (b) Clinical Protocol Page 57
LY90001411. References
Albert i KG, Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultati on. Diab Med . 1998;15(7):539 -553.
Bennett P. Classificat ion and diagnosis of diabetes mellitus and impaired glucose tolerance. In: 
Pi[INVESTIGATOR_157700], William G, editors. Textbook of diabetes. Vol. 1. 1st ed. Oxford: Blackwell 
Scientific Publicat ions; 1991:p [ADDRESS_451473] KF, Cowie CC. The prevalence of meet ing A1C, 
blood pressure, and LDL goals among people wit h diabetes, 1988 -2010. Diab Care . 
2013;36(8):2271 -2279.
Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes thro ugh the life span: a posit ion 
statement of the American Diabetes Associat ion. Diab Care. 2014;37(7):2034 -
2054.
[DCCT] The Diabetes Control and Co mplications Trial Research Group. The effect of intensive 
treatm ent of di abetes on the development and progress ion of long -term com plicat ions in 
insulin -dependent di abetes m ellitus. N Engl J Med . 1993;329(14):977-986.
EURODIAB ACE Study  Group. Vari ation and trends in incidence of childhood diabetes in 
Europe. Lancet . 2000;355(9207):873-876.
Hum alog: EPAR :Product I nformation. European Medicines Agency Web site. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Summary _for_the_public/human/000088/WC500050328.pdf. Accessed August 14, 2017.
Hum alog [package insert]. Indi anapo lis (IN): Eli Lilly and Co mpany; 2017.
Levy  M, Cel ermajer DS, Bourges -Petit E, Del Cerro MJ, Bajo lle F, Bonnet D. Add- on therapy  
with subcutaneous treprostinil for refractory  pediatri c pulmo nary hypertensi on. J Pediatr . 
2011;158(4):584 -588.
Lipman TH, Levitt Katz LE, Ratcliffe SJ, Murphy KM, Aguilar A, Rezvani I, Howe CJ, Fadia S, 
Suarez E. Increasing incidence of t ype 1 diabetes in youth: twenty years of the Philadelphia 
Pediatric Di abetes Regi stry. Diab Care. 2013;36(6):1597 -1603.
Orenitram (treprostinil) [prescribing informat ion]. Research Triangle Park, NC: United 
Therapeut ics Corp; 2016. 
Pettitt DJ, Tal ton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, Liese AD, Linder B, 
Mayer -Davis EJ, Pi[INVESTIGATOR_92746] C, Say dahSH, Standiford DA, Hamman RF; SEARCH for Diabetes 
in Youth Study  Group. Prevalence of diabetes in U.S. y outh in 2009: the SEARCH for 
diabetes in y outh study . Diab Care . 2014;37(2):402 -408.
DiMegli o LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pi[INVESTIGATOR_140195] K, Maahs DM; Internat ional 
Society for Pedi atric and Ado lescent Diabetes. ISPAD Clinical Pr actice Consensus Guidelines 
2018. Glycemic control targets and glucose monitoring for children, adolescents, and young 
adults wi th diabetes .Available at: 
https://cdn.ymaws.co m/www.ispad.org/resourc e/resmgr/consensus_guidelines_2018_/8.glyce
mic_control _targets_a.pdf .Accessed October 24, 2018.
I8B-MC-ITSB (b) Clinical Protocol Page 58
LY900014[PMR] Pharmaceut ical and heal thcare market in CEE and CIS. Remodulin approved in 
22European countries, also Poland. PMR Web site. Available at :
http://www.cee pharma.com/news/[ZIP_CODE]/remodulin -approved- in-22-european -countri es-also-
poland. Published September 1, 2005. Accessed September 16, 2016.
Ratitch B, O’Kelly M, Tosiello R. Missing data in clinical trials: fro m clinical assumpt ions to 
statist ical analysis using pattern mixture models. Pharm Stat . 2013;12(6):337 -
347.
Remodulin [package insert]. Research Triangle Park, NC: United Therapeut ics C orporati on; 
2018. Available at: https://www.remodulin.co m/downloads/remodulin -
prescribinginformat ion.pdf. Accessed October 15, 2018.
Seaquist ER, Anderson J, Childs B, Cry er P, Dagogo -Jack S, Fish L, Heller SR, Rodriguez H, 
Rosenzweig J, Vigersky  R. Hypog lycemia and diabetes: a report of a workgroup of the 
American Diabetes Associat ion and the Endocrine Societ y. Diab Care. 2013;36(5):[ADDRESS_451474] imation of GFR in children and ado lescents. Clin J 
Am Soc Nephrol. 2009; 4(11):1832 -1843.
Tyvaso [prescribing informat ion]. Research Triangle Park, NC: United Therapeutics 
Corporati on; 2014.
I8B-MC-ITSB (b) Clinical Protocol Page 59
LY90001412. Appendices
I8B-MC-ITSB (b) Clinical Protocol Page 60
LY900014Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product that does not 
necessarily have a causal relationship with this treatment.  An adverse event 
can therefore be any unfavorable and unintended sign (including an abnormal 
laborato ry finding), sy mptom , or disease temporally associated with the use 
of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analy sis of covariance
AST aspartate aminotransferase
BG blood glucose
BID twice daily (twice a day)
Blinding/masking A single -blind study is one in which the investigator and/or his staff are aware 
of the treatment but the patient is not, or vice versa, or when the sponsor is 
aware of the treatment but the investigator and/his staff and the patient are 
not.
A double -blind study is one in which neither the patient nor any of the 
investigator or sponsor staff who are involved in the treatment or clinical 
evaluation of the patient s are aware of the treatment received.
BMI body mass index
CGM continuous glucose monitoring
CI confidence interval
Cmax maximum drug concentration
Produ ct complaint Product complaints are a customer’s written, electronic, or oral 
communication that alleges deficiencies related to the identity, quality, 
durability, reliability, safety, effectiveness, or performance of a Lilly product 
after it is released for distribution.
CRF case report form
CRP/CRS clinical research physician: Individual responsi ble for the medical conduct of 
the study .  Responsibilities of the CRP may be performed by a physician,
clinical research scientist, global safety physician, or other medical officer.
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451475]
FDA Food and Drug Administration
FGM flash glucose monitoring
GFR glomerular filtration rate
HbA1c hemoglobin A1c
IB Investigator’s Brochure
ICF informed consent form
IP investigational product: A pharmaceutical form of an active ingredient or 
placebo being tested or used as a reference in a clinical trial, including 
products already on the market when used or assembled (formulated or 
packaged) in a way different from the authorized form, or mark eted products 
used for an unauthorized indication, or marketed products used to gain further 
information about the authorized form.
ITT Intentio n-to-treat:  The principle that asserts that the effect of a treatment 
policy  can be best assessed by [CONTACT_362310] g on the basis of the intention to treat 
a patient (that is, the planned treatment regimen) rather than the actual 
treatment given.  It has the consequence that patients allocated to a treatment 
group should be followed up, assessed, and analyzed as member s of that 
group irrespective of their compliance to the planned course of treatment.
IWRS interactive web response system
LLT lowest level term
LOCF last observation carried forward
LS least-squares
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451476] model repeated measure
NIM noninferio rity margin
NPH neutral protamine Hagedorn
PAH pulmo nary artery  hypertension
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PP per-protocol
PPG postprandial glucose
PT preferred term
QD once a day
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
Screen The act of determining if an individual meets minimum requirements to 
become part of a pool of potential candidates for participation in a clinical 
study.
SD standard deviation
SMBG self-monitored blood glucose
SOC system organ class
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
T1D type 1 diabetes
TBL total bilirubin level
TDD total daily insulin dose
I8B-MC-ITSB (b) Clinical Protocol Page 63
LY900014TEADA treatment -emergent anti drug antibody
TEAE treatment -emergent adverse event:  An untoward medical occurrence that 
emerges during a defined treatment period, having been absent pretreatment, 
or worsens relative to the pretreatment state, and does not necessarily  have to 
have a causal relationship with this treatment.
ULN upper limit of normal
US [LOCATION_002]
WHO World Health Organization
I8B-MC-ITSB (b) Clinical Protocol Page 64
LY900014Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests
HematologyaClinical Chemistrya
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase (ALP)
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Chloride
HbA1caMagnesium
Cholesterol
UrinalysisaGlucose (nonfasting)
Specific gravity Albumin
pH Total protein
Protein
Glucose Pregnancy Test (females only)
Ketones Serum pregnancy testa
Blood Urine pregnancy testb
Urine leukocyte esterase
Nitrite Serologya
Anti-insulin lispro antibodies
Abbreviations:  HbA1c = hemoglobin A1c; RBC = red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated laboratory.
bAssay ed by [CONTACT_5737] -or investigator -designated laboratory .
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451477] igator is responsible for the following:
Ensuring that the patient/patient’s legal representative understands the nature of 
the study , the potential risks and benefit s of parti cipating in the study , 
and that 
their parti cipat ion is vo luntary.
Ensuring that informed consent is given by [CONTACT_57996].  
This includes obtaining the appropriate signatures and dates on the ICF prior to 
the perform ance of any  protocol  procedures and pri or to the administrati on of  
investigat ional product.
Answering any quest ions the patient/ patient’s legal representative may have 
throughout the study  and sharing in a timely manner any  new informat ion that 
may be relevant to the patients/ patient’s legal r epresentati ve’swillingness to 
continue his or her participat ion in the study.
Ensuring that a copy  of the ICF is provi ded to the parti cipant or the participant’s 
legal representative and is kept on file.
Ensuring that the medical record includes a stateme nt that wri tten inform ed 
consent was obtained before the participant was enrolled in the study  and the date 
the wri tten consent was obtained. The authorized person obtaining the informed 
consent must also sign the ICF .  
A legal representative must give i nformed consent for a child to participate in this study .  In 
addition to inform ed consent given by [CONTACT_80518], the child may  be requi red to give 
docum ented assent, if capable as requi red per l ocal laws .
Appendix 3.1.[ADDRESS_451478] (ERB) was properly  consti tuted and convened as required by [CONTACT_266482] (ICH) guidelines and other applicable laws and regu lations.
Docum entati on of  ERB approval  of the protocol and the ICF and Assent Form must be provided 
to Lilly  before the study  may begin at the invest igative site(s).  Lilly or its representatives must 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451479] igative 
site(s).  All  ICFs must be com pliant wi th the ICH gui deline on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
theprotocol and related amendments and addenda ,current Investigator Brochure 
(IB)Package Insert, or Summary of Product Characterist ics and updates during 
the course of the study
inform ed consent form  and Assent Form
other relevant docum ents ( for example , curri cula vi tae, adverti sements)
Appendix 3.1. 4. Regulato ry Considerations
This study  will be conducted in accordance wit hthe protocol and with the:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences Internat ional Ethi cal Guidelines
applicable ICH GCP Guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party .
Appendix 3.1. 5. Investigator Information
Pediatric endocrino logist or diabetologist, adult endocrino logist or diabetologist, internal 
medicine, or primary care physicians with experience in the care of pediatric patients with T1D
will part icipate as invest igators in this clinical trial.
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
[CONTACT_221083], indicating agreement 
that, to the best of h is or her knowledge, the report accurately describes the conduct and results 
of the study .
An invest igator will be selected by [CONTACT_362311].  The sponsor’s responsible medical officer and statistician w ill approve the final 
CSR for thi s study , confi rming that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
I8B-MC-ITSB (b) Clinical Protocol Page 67
LY900014Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi de sponsor start -up training to instruct the investigators and study 
coordinators.  This training will give instruction on the protoc ol, the com pletion 
of the CRFs, and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_129237], tel ephone, and/or fax
review and verify  data reported to detect potential e rrors
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives and/or regulatory  agencies at any  time.  Inv estigators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  These might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor .  
An electronic data capture (EDC) system  will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  [CONTACT_32864] -provided EDC system.  T he invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_11003].
Addit ionally , clinical  outcom e assessment data (questionnaires and self -reported di ary data) will 
be co llected by [CONTACT_423], via a paper source document and will be transcribed by [CONTACT_1275] -site personnel into the EDC system.
Data collected via the sponsor- provided data capture system(s) will be stored at third -party  sites.  
The invest igator will have cont inuous access to the data during the study and unt il 
decommissio ning of the data capture sy stem (s).  Pri or to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged b y a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451480] igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Appendix 3.3.2. Discontinuation of the S tudy
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3. 4. Publication Policy
The publicat ion policy for Study  I8B-MC-ITSB is described in the Clinical Trial Agreement .
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451481]
GGT Alkaline Phosphatase Isoenzymesa
CPK
Anti -Smooth Muscle Antibody (or Anti-Actin 
Antibody)a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451482] laboratory  and immunogenicit y 
tests during the study .  Fewer samples may  actually  be taken, but thi s will not require a protocol 
amendment.
Protocol I8B-MC -ITSB Sampling Summary
Abbreviation:  ED = early discontinuation; V = visit .
aFor rescreening patients, an additional Visit 1 blood volume draw is required.
bAdditional samples may be drawn if needed for safety purposes.
cBased on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow -up, in consultation with Lilly -designated Medical Monitor.Study Visit
V1a V4 V7 V10 V15ED Total
Estimated blood volumeb,mL 10 6.5 6.5 6.5 10 10 39.5
Hepatic monitoringc3-30 mL
I8B-MC-ITSB (b) Clinical Protocol Page [ADDRESS_451483] pubertal females o f childbearing potential are defined as children and ado lescents ≥12 years 
of age or <[ADDRESS_451484] ive method of contraception .  
Methods of Contraception
Highly Effective Methods of Contraception
Combined oral contraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382]
NuvaRing®
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 lb.or 90 kg
Total abstinence
Vasectomy
Females who are not of childbearing potential include those who have undergone or who have:
a.Female sterilizat ion
b.Hysterectomy
c.Menopause
d.Mullerian agenesis (Mayer -Roki tansky -Küster -Hauser syndro me [also referred to as 
congenital absence of the uterus and vagina])
I8B-MC-ITSB (b) Clinical Protocol Page 72
LY900014Appendix 7. Protocol A mendment History
Protocol  I8B-MC-ITSB (a) A Prospective, Randomized, Double -Blind Com parison of 
LY900014 to Humalog with an Open -Label Postprandial LY900014 Treatment Group in 
Children and Ado lescents wi th Type 1 Di abetes; PRONTO -Peds has been amended.  The new 
protocol  is indicated by  [CONTACT_61504] ( b) and will be used to conduct the study  in place of a ny 
preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are described in the 
following table:
I8B-MC-ITSB (b) Clinical Protocol Page 73
LY900014Amendment Summary for Protocol I8B-MC-ITSB Amendment ( b)
Section # and Name [CONTACT_362312] C hange Brief Rationale
Table ITSB.1 Schedule of Activities Added new footnote to Screen Clarification for restart at Visit 1 for those patients 
who need to rescreen .
6.1 Inclusion Criteria Changed insulin daily dose range and HbA1c 
acceptable values Changes allow for younger and active children 
using smaller doses and adolescents who require 
more insulin during puberty. Will allow broader 
range of patients including those who are in good 
control.
6.1 Inclusion Criteria Added language defining postpu bertal females Change clarified definition of postpubertal females 
already  noted in Appendix 6.
6.4 Screen Failures Added 1 rescreen allowed Change made to allow 1 rescreen to patients who 
who had a screen fail or unexpectedly had to 
discontinue due to COV ID-19enrollment pause .
Appendix 5 Sampling Summary Added footnote on V1 Change made to include information on 
rescreening .
I8B-MC-ITSB (b) Clinical Protocol Page 74
LY900014Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
Table ITSB.1. Schedule of A ctivities
Screen a Lead -In Treatment Perio dSafety 
Follow -UpEDa
b
eCRF Visit Number 1 2 3bc 4 5bc 6bc 7 8cb 9bc 10 11bc12 13bc14bc15 801 cd ED
Weeks from Randomization −5 −4 -2 0 2 4 6 8 10 12 15 18 21 24 26 28
Visit Window (±days) [ADDRESS_451485] Personal CGM/FGM use 
(yes/no)X
Height ef X X X X X
Weight X X X X X X X X
Vital signs (sitting SBP, DBP ,and 
HR) fgX X X X X XXX
Concomitant medications X X X X X X X X X X X X X X X X X
Adverse events and product 
complaintsX X X X X X X X X X X X XXX X
Focused physical exam (including 
skin evaluation)gh X X X X X XXX
Basal insulin dose assessment ih X X X X X X X X X X X X X X X
Basal insulin dose titration ij X X X X X X X X X
I8B-MC-ITSB (b) Clinical Protocol Page 75
LY900014Screen a Lead -In Treatment Perio dSafety 
Follow -UpEDa
b
eCRF Visit Number 1 2 3bc 4 5bc 6bc 7 8cb 9bc 10 11bc12 13bc14bc15 801 cd ED
Weeks from Randomization −5 −4 -2 0 2 4 6 8 10 12 15 18 21 24 26 28
Visit Window (±days) 3 3 3 7 7 7 7 7 7 7 7 7 7 7 7
Ancillary Supplies/Diaries/IP
Dispense blood glucose meter and 
ancillary  supplies and complete 
training j,k,lX X X X X
Diabet es education and nutrition 
counseling klX
Dispen se study diaries and 
complete training klX X X X X
Collec tstudy diaries X X X X X X
Dispen se IP X X X X X
Train on collecting [ADDRESS_451486], serum/urine 
(applicable females only) mnX X
aPatients who rescreen will start at Visit 1. .
I8B-MC-ITSB (b) Clinical Protocol Page 76
LY9000146.1. Inclusion Criteria
Patients are eligible to be included in the study ,only if they meet all  the f ollowing cri teria at 
screening:
[5]Have been treated with only one [ADDRESS_451487] 90 days: 
a.insulin glargine U- 100 (QD or BID), or
b.insulin detemir U- 100 (QD or BID), or
c.insulin degludec U -100 (QD)
[6]Use a total daily dose of insulin 0. 35to ≤1.95U/kg.
a.TDD can be the average of previou s 3 to 7 day s 
[7]Have a nHbA1c value ≥6.5% and ≤9.5%, HbA1c value ≤9.9% according to 
the central  laboratory .  
[8]Male patients: 
a.no male contraception required ,except in co mpliance wit h speci fic local 
government regulat ion
[9]Female pat ients of childbearing potenti al:
a.Post pubertal females o f childbearing potential are defined as children and 
adolescents ≥12 y ears of age or <[ADDRESS_451488] onset of 
menses  
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) may not be 
rescreened.  Retests are also not allowed, except for cases when results are not available fro m the 
original  sample. or were requi red to unexpectedly  discontinue from  the study  during screening or 
lead-in period (e.g., due to enrollment pause related to the COVID -19 public health emergency) 
are allowed 1 rescreening.  
All patients that rescreen will restart at Visit 1 and complete all screening procedures. 
I8B-MC-ITSB (b) Clinical Protocol Page 77
LY900014Appendix 5. Sampling Summary
Protocol I8B -MC -ITSB Sampling Summar y
Abbreviation:  ED = early discontinuation; V = visit .
aFor rescreening patients, an additional Visit 1 blood volume draw is required.
abAdditional samples may be drawn if needed for safety purposes.
bcBased on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow -up, in consultation with Lilly -designated Medical Mo nitor.Study Visit
V1aV1 V4 V7 V10 V15ED Total
Estimated blood volume ,ab,mL 10 6.5 6.5 6.5 10 10 39.5
Hepatic monitoringbc3-30 mL
Leo Document ID = 6ec65f49-6319-4aff-8f32-73e9b233e460
Approver: 
Approval Date & Time: 30-Apr-2020 19:17:05 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 30-Apr-2020 19:33:05 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]